Effect of uptake pathway on non-viral gene delivery in vitro and in vivo by Shum, Wing
   
 
 
 
 
 
 
 
 
 
© 2013 Wing Tat Victor Shum
  
 
 
 
 
 
 
EFFECT OF UPTAKE PATHWAY ON NON-VIRAL GENE DELIVERY IN VITRO AND IN 
VIVO 
 
 
 
 
 
 
BY 
 
WING TAT VICTOR SHUM 
 
 
 
 
 
 
 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in Chemical Engineering 
in the Graduate College of the 
University of Illinois at Urbana-Champaign, 2013 
 
 
 
 
 
Urbana, Illinois 
 
Doctoral Committee: 
 
Professor Daniel Pack, Chair 
Professor Hong Yang 
Assistant Professor Mary Kraft 
Professor Edward Roy 
ii 
 
ABSTRACT 
Efficient non-viral gene delivery often involves the conjugation of a cell-specific ligand to the 
vector, which directs the vector to its intended target through binding to a cellular receptor 
followed by internalization via endocytosis. However, little is known in terms of how the various 
endocytosis pathways affect the performance of the delivery vehicle. Previously, the Pack lab 
has demonstrated that caveolin-mediated endocytosis is important to in vitro polyethylenimine 
(PEI)- and polyamidoamine (PAMAM)-mediated gene delivery in HeLa cells through the use of 
small molecule drugs and small-interfering RNA [1-2]. The goal of this thesis is to further 
elucidate the effects of cellular uptake mechanism on non-viral gene delivery in vitro and in vivo 
utilizing a small hairpin RNA (shRNA) Tet-on system. Specifically, we have investigated the 
effects of clathrin-dependent endocytosis and caveolin-dependent endocytosis on the efficacy of 
PEI and PEI-derivative gene delivery in HeLa and MDA-MB-231 cell cultures and xenograft 
tumors.  
 
First, we attached transferrin and folate ligands to PEI to direct internalization by clathrin- and 
caveolin-mediated mechanisms, respectively, and transfected HeLa and MDA-MB-231 cells 
with targeted and untargeted PEI in the presence of small molecule drugs that inhibit clathrin- or 
caveolin-mediated endocytosis. We demonstrated through these studies that caveolin-dependent 
endocytosis is important to successful PEI-mediated gene delivery in both HeLa and, for the first 
time, MDA-MB-231 cells. In addition, a similar endocytic pathway study was performed using 
biodegradable PEI and acetylated PEI, which have demonstrated superior gene delivery 
capability compared to unmodified PEI in previous work [3-4]. The data show that regardless of 
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structure, size, molecular weight, or zeta potential of the PEI-derivative polyplexes, caveolin-
dependent endocytosis was critical to effective gene delivery.  
 
In order to further understand the impact of endocytic pathways on gene delivery efficiency in 
vitro, we modified HeLa and MDA-MB-231 cells to express small hairpin RNA (shRNA) that 
inhibit expression of clathrin, caveolin, or lamin A/C (negative control) protein expression 
(HeLa-CLTC, HeLa-CAV, HeLa-LAM, 231-CLTC, 231-CAV, and 231-LAM)  in the presence 
of tetracycline. Using the shRNA Tet-on system, we demonstrated ~90% clathrin knockdown 
and ~60% caveolin knockdown in both modified HeLa and MDA-MB-231 cells.  Subsequently, 
utilizing this inducible shRNA protein knockdown system, we transfected modified shRNA cells 
using both targeted and untargeted PEIs and confirmed that caveolin-dependent endocytosis is 
more important than clathrin-dependent endocytosis to PEI-mediated gene delivery, which 
corroborates the results observed in unmodified cell lines using small-molecule endocytosis 
inhibitors.  
 
Lastly, we investigated the effect of clathrin-dependent and caveolin-dependent endocytosis on 
in vivo PEI-mediated gene delivery in a xenograft murine tumor model. By inoculating modified 
shRNA cells into NIH-III nude mice, we created a xenograft tumor model that allows us to 
induce CLTC and CAV protein knockdown inside the tumor. Using this Tet inducible system, 
we demonstrated that the mice fed with Tet-containing water, compared to those fed with water 
only, show over 50% target protein knockdown in modified MDA-MB-231 cells and 90% CLTC 
knockdown and 35% CAV knockdown for modified HeLa cells. By transfecting shRNA 
modified tumors intratumorally with PEI polyplexes, PEI gene delivery efficacy was 15-fold and 
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2.5-fold higher for modified HeLa and MDA-MB-231 tumors, respectively, when comparing 
clathrin- versus caveolin-dependent endocytosis inhibition, although the improvement for 
unmodified MDA-MB-231 tumors was statistically insignificant. The results confirmed that 
caveolin-dependent endocytosis was more important to in vivo PEI-mediated gene delivery than 
clathrin-dependent endocytosis, which is in good agreement with in vitro data using both small 
molecule drugs and Tet inducible protein knockdown. 
 
In conclusion, these studies of intracellular trafficking and its effect on PEI gene delivery 
efficacy in cancer cell lines and tumors will aid researchers in designing more efficient non-viral 
gene delivery vectors for cancer gene therapy, by synergistically combining the design of cell 
targeting ligands and the understanding of cellular uptake mechanism for polymeric carriers. 
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Chapter 1 
Introduction 
 
1.1 Gene Therapy in Medicine 
Gene therapy can be defined as the treatment of human disease through the transfer of 
genetic material into specific cells within a patient [1]. For example, a therapeutic gene 
may be inserted into the genome of the targeted cells to replace an errant gene [2]. This is 
a promising technique for curing diseases that are caused by genetic mutations, which can 
lead to malfunction or deficiency of proteins. The causes of diseases like hemophilia, 
cystic fibrosis, and severe combined immunodeficiency (SCID) are related to specific 
aberrant genetic mutations [3-5]. Gene therapies are also being studied for conditions that 
are not directly attributed to a defective gene, such as Alzheimer’s disease, cardiovascular 
diseases, and cancer. Such treatments involve inserting genes to increase the production 
of specific proteins, to change gene expression, or to kill disease-causing cells by 
producing cytotoxic growth factors or proteins [6-9]. By genetically modifying patients’ 
cells to produce therapeutic proteins, gene therapy has the potential to eliminate some 
problems associated with therapeutic drugs, namely poor bioavailability, high cost, and 
the necessity for frequent doses [10].  
 
With the breakthrough of the Human Genome Project and the advancement of RNA and 
DNA technology, the particular human genes that correspond to many diseases or 
therapeutic protein production have been identified, and the promise of gene therapy has 
reached new heights. According to the National Institutes of Health, there are currently 
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1754 gene therapy clinical studies underway [11]. However, due to various limitations of 
delivering therapeutic RNA or DNA into target cells and/or tissues, gene therapy has yet 
to reach its full potential [12-13]. Currently, the most challenging aspect of gene therapy 
is to deliver a therapeutic gene into target cells and/or tissues efficiently and without 
significant side effects. Most current gene delivery methods suffer some critical 
drawbacks that plague new therapies from getting past the clinical trial development 
phase [14-15]. Much research is needed to better understand the cellular dynamics of 
gene delivery, and to design molecularly and clinically effective gene therapy procedures. 
 
The most common gene delivery method used in clinical testing involves direct injection 
of therapeutic genetic material using either viral or non-viral vectors to target specific 
cells in the patient’s body, called in vivo gene delivery. In vivo delivery generally does 
not require surgery to extract diseased tissues and, more importantly, allows therapeutic 
genes to reach more transient targets like moving cells. An example of a disease treated 
using in vivo gene delivery is cystic fibrosis (CF). CF is an inherited genetic disease that 
affects the lungs and digestive system, causing difficulty in breathing, lung infection, and 
often early death. The cause of CF is a mutation in the gene that is responsible for the 
production of cystic fibrosis transmembrane conductance regulator (CFTR), a protein 
found in the epithelial cells of the lungs and pancreas [16]. The genetic mutation of 
CFTR affects the movement of chloride and sodium ions in and out of the cells, resulting 
in an imbalance of ion concentration in the body and the formation of a layer of thick 
mucus that blocks the airways and causes lung infections [17]. Research has shown that 
to prevent the development of CF, only 5-10% of the normal gene expression of CFTR is 
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needed [18]. Because of the relatively low therapeutic efficiency needed to treat CF, in 
vivo gene therapy has become an ideal treatment option. Several clinical studies have 
been conducted using both viral and non-viral in vivo gene therapy to treat CF [19]. 
Approximately one-third of the patients recovered ~20% ion concentration [20]. 
Although much research is needed to increase in vivo gene therapy’s efficacy, the initial 
success of these trials shows the potential of in vivo gene therapy as a safe alternative 
technique to treat genetic diseases. 
 
Besides genetic diseases, another major potential treatment area for in vivo gene therapy 
is cancer. Currently, there are about 647 FDA-approved clinical trials using various in 
vivo gene therapies to treat tumors [21]. Cancer gene therapy can be summarized into 
four major approaches: 1) to replace the missing or altered gene that gives rise to cancer 
by substituting it with normal copies of the gene; 2) to activate the patient’s immune 
system against cancer by inserting a gene that stimulates the patient’s immune response; 
3) to insert a gene into cancer cells to make them more susceptible to radiation or 
chemotherapy; or 4) to induce the expression of a “suicide gene” in cancer cells that will 
trigger the patient’s immune response against them or apoptosis [22]. Regardless of 
approach, there are some barriers that need to be overcome in order for in vivo gene 
therapy to be used for cancer treatment. Researchers need to ensure that the gene is 
carried specifically to the cancer cells (not the surrounding healthy cells), is inserted into 
the correct location in the genome, and does not cause any harmful mutations. 
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1.2  Gene Delivery Methods 
The key component of most gene therapy is to alter the target cells to produce the 
therapeutic protein to treat the particular disease. In order for gene therapy to work 
properly, the gene encoding for the corresponding protein must be delivered into the 
target cells’ nucleus for the gene to be transcribed and translated sufficiently. Two of the 
common physical methods used to directly inject DNA into a patient’s cells are 
electroporation and gene gun. For electroporation, the target cells are exposed to intense 
electric pulses, where the cell membranes are disrupted and permeabilized, allowing 
DNA to transport into the cells [23]. This method generally damages a large number of 
target cells, which makes it a non-ideal technique for gene therapy, though recent 
research has shown that high voltage electroporation in pigs can destroy target cells while 
surrounding cells remain unaffected [24]. Gene guns basically utilize helium propellant to 
shoot DNA-loaded gold nanoparticles into target cells [25]. Though efficient for in vitro 
experiments, gene guns require large physical force to shoot the gene into tissues, often 
causing tissue damage and rendering the technique non-ideal for in vivo experiments. 
Due to the physical damage that both of the above methods cause, the more commonly 
researched gene delivery methods involve encapsulating the therapeutic DNA in viral 
vectors (adenovirus, retrovirus, etc.) or non-viral vectors (cationic polymers, lipids, etc.) 
to transport the DNA into the target cells [26-27].  
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1.3  Viral Gene Delivery Vectors 
 
1.3.1 Viral Vectors and Their Advantages 
A virus is a small infectious agent that is programmed to infect a living organism (the 
host) and hijack the host’s cellular mechanisms to reproduce the virus particle [28]. 
Generally, viruses consist of genetic material (DNA or RNA), a capsid protein coating 
that protects the genes, and/or a lipid envelope that protects the core when it is outside a 
cell. The two most common types of viruses used in gene therapy are retroviruses and 
adenoviruses. For retroviruses, the genetic material at the core is RNA, and the maximum 
size limit of the RNA is ~10 kbp. The capsid of a retrovirus is protected by a lipid 
envelope. The retrovirus, upon entering a host cell, reverse transcribes its RNA, 
integrates the corresponding DNA into the host’s genome, and then replicates itself as 
part of the host’s DNA. Unlike retroviruses, adenoviruses’ genetic material is DNA, and 
the maximum size limit of the DNA is ~35 kbp. Adenoviruses are nonenveloped viruses, 
and their DNA is only delivered to the host’s nucleus without incorporating into the 
host’s genome. Adenoviruses are capable of infecting both dividing and non-dividing 
cells, while retroviruses can only infect dividing cells. 
 
Due to viruses’ natural ability to transfer genes into cells, they have become a promising 
candidate for gene delivery vectors. However, all the potentially infectious genes and 
immunogenic capsid proteins must be removed from the viruses before they can be used 
for gene therapy. Once these genes and proteins are removed, therapeutic genes can be 
inserted into the viruses’ capsid, creating an extremely efficient virus-based therapeutic 
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gene delivery carrier. Unfortunately, it is difficult to remove completely all the 
potentially harmful components of a virus, and those that may remain behind pose a 
serious pathogenic threat to the patient upon administration. Even though viruses show 
promise as an efficient gene delivery vehicle, they still suffer many drawbacks, namely 
oncogenicity, immunogenicity, and lack of cell targeting capability that hinder them from 
being FDA-approved as a viable therapy.  
 
1.3.2 Immunogenicity 
As mentioned above, viral genes should be removed in order for a virus to be safely used 
as a gene delivery vector. However, even if all viral components are extracted, a large 
dosage of viruses injected into a patient may still trigger the patient’s immune system, 
resulting in either a serious immune response or greatly reduced gene delivery efficiency. 
The danger of fatal immune response caused by viral gene therapy was highlighted 
during a clinical trial in 1999 using an adenovirus as a delivery vector to treat ornithine 
transcarbamylase deficiency (OTCD) [29-30]. OTCD is a genetic disorder caused by the 
mutation of a gene that is normally responsible for the liver’s production of ornithine 
transcarbamylase, an enzyme used to remove ammonia from the bloodstream. A large 
dose of adenovirus containing the therapeutic replacement gene was administered to the 
patient, causing an over-release of inflammatory cytokines and eventual systemic 
inflammatory response syndrome (SIRS). As a result of SIRS, the patient developed 
acute respiratory distress syndrome (ARDS), which proved fatal to the patient [31]. The 
death that occurred during this clinical trial led to a temporary suspension of all gene 
therapy trials by the FDA [32]. 
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To prevent further immunogenicity-related deaths, researchers began to explore other 
types of viruses that possess less or no immunogenicity, such as adeno-associated viruses 
(AAVs). AAVs do not possess the pathogenicity associated with other types of viruses, 
and they currently have not been found to cause any human diseases [33]. AAVs are 
currently being tested in many clinical trials to treat various genetic diseases and prostate 
cancer [34]. There are a few limitations to using AAVs for gene therapy: 1) AAVs 
possess low cloning capability, in the absence of contaminating wild-type AAV or helper 
adenovirus, making them difficult to mass produce, 2) AAVs have a small genome size 
(4.8kbp), which limits the type of therapeutic gene that could be inserted into the virus, 
and 3) AAV infection generally leads to an increase in antibody production, which could 
neutralize and reduce its efficacy [35-36]. Regardless of the type of virus used for gene 
therapy, even if the viral vectors do not trigger a fatal reaction, any human immune 
response will greatly reduce the efficiency of the viral delivery vector by either 
eliminating the viruses before infection or killing the infected cells before the inserted 
gene is expressed [37]. 
 
1.3.3 Oncogenicity 
One of the advantages of viral gene delivery is viruses’ ability to carry genes efficiently 
into host cells. If the genetic cargo is inserted into the correct genomic location, viral 
gene therapy could provide the desired long-term therapeutic protein expression. 
However, if the gene is inserted randomly and disrupts normal gene expression or 
triggers an oncogene, cancer may develop as a result. Since adenoviruses do not insert 
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their DNA into the host’s genome, it is unlikely that adenoviruses will cause undesirable 
gene integration. AAVs do have the ability to integrate their DNA into the host’s 
genome, but they primarily do so in a specific site on human chromosome 19 [38-39]. 
Unlike adenoviruses and AAVs, retroviruses present the threat of undesired gene deletion 
or activation and genetic mutation due to random DNA integration into the host’s 
genome. Cancer-inducing retrovirus gene insertion was the cause of the leukemia 
development in the children treated for X-SCID in early retrovirus clinical trials [105-
106]. Besides gene integration issues, native components of the viruses themselves might 
also cause cancer under certain conditions [40-41]. 
 
1.3.4 Development and Production 
The production of retroviral vectors for gene therapy involves two components: the 
retrovirus and the retrovirus packaging cell line. The retrovirus carries all the essential 
viral genes except the gene for viral proteins, which is provided by the retrovirus 
packaging cell line. By infecting the packaging cell line with retrovirus, one can produce 
retroviral vectors with desired properties or titer [42-43]. This production process has two 
major drawbacks: 1) the size of the gene that can be inserted into the retroviruses is 
limited to about 10 kbp and may not be appropriate for the therapeutic gene of interest; 
and 2) the expression of pathogenic viral proteins from any intact viral genes could 
trigger the host’s immune response. Because of these potential downfalls, a safer 
alternative virus production pathway involving gutted adenoviruses is being explored. In 
this case, the viruses only consist of the gene for packaging and replication. Larger 
therapeutic genes can be inserted into gutted viruses, reducing the risk of viral proteins 
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due to the removal of excess viral genes from the process. However, this process is more 
complex and labor-intensive compared to regular retrovirus production [44-46]. 
 
Most current virus production is targeted for lab bench-scale experiments. Both the 
packaging cell lines and purifications involved are expensive and difficult to scale up for 
mass production of viruses [47-48]. Without a more efficient and cost-effective method 
to mass produce viruses, viral gene therapy will remain a highly individualized and 
expensive treatment if approved.  
 
1.4 Non-Viral Gene Delivery Vectors 
Given the inherent properties of viral vectors in efficiently infecting various cell types 
and transferring genetic materials into the cell’s nucleus, viruses have been extensively 
studied in clinical trials for gene therapy. However, as discussed above, viruses present 
many problems for in vivo gene therapy, including oncogenicity, pathogenicity, and cost. 
As a result, researchers have been exploring alternative materials that would provide 
similar gene delivery properties as viruses yet do not trigger immune responses from the 
patient and are relatively inexpensive to synthesize. Two such materials that are being 
studied to replace viral vectors are cationic lipids and polymers. The cationic surface 
charge of these non-viral vectors allows complexation with negatively charged DNA to 
form a shield to protect DNA from degradation. Some common lipids and polymers used 
in gene delivery research are shown in Figure 1.1. Unlike viruses, synthetic vectors need 
to overcome many barriers, both intracellular and extracellular, for successful 
transfection. A basic schematic of the process of non-viral gene delivery is shown in 
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Figure 1.2. Much research has been invested into increasing the efficiency of non-viral 
vectors by improving their ability to bind to the cell surface and to escape cellular 
degradation mechanisms. 
 
1.4.1 Advantages and Disadvantage of Non-viral Gene Delivery Vectors 
One of the main advantages of using non-viral vectors over viral vectors in gene delivery 
is that non-viral vectors are generally non-immunogenic and non-pathogenic. More 
importantly, unlike viruses, synthetic vectors do not insert genes into the cell’s genome, 
thus eliminating the risk of random insertion mutation. A summary of advantages and 
disadvantages of viral and non-viral vectors in gene delivery is listed in Table 1.1. Even 
though non-viral vectors show many good qualities as a gene delivery carrier, the main 
problem that plagues non-viral vectors from being a viable gene therapy option is its poor 
transfection efficiency compared to viruses. To understand this inefficiency in non-viral 
gene therapy, one needs to understand the cellular barriers and mechanisms involved in 
order for synthetic vehicles to deliver therapeutic gene into the cell’s nucleus. 
 
1.4.2 Extracellular Barriers 
Unlike viruses, non-viral gene delivery vectors do not possess the natural ability of 
infecting cells and inserting genes into the host’s nucleus. Polymer/DNA complexes 
(polyplexes) need to overcome many obstacles in order to reach and then enter the cells. 
For in vivo experiments, once the polyplexes are injected into the animal, they need to 
first withstand the degradative enzymes and serum proteins present in the blood stream. If 
cationic polymers do not condense the gene tightly or completely shield the gene from 
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the enzyme, the gene will be digested, resulting in reduced delivery efficiency. Also, 
many serum proteins are negatively charged, which causes them to bind with the 
polyplexes that exhibit positive surface charge. If too much serum protein attaches to the 
polyplexes, the aggregates that form may be accumulated or filtered out by the liver or 
spleen due to various factors, including size, binding of complement proteins, etc. [49]. 
One way to reduce serum protein aggregation is to shield the positive surface charge of 
the polyplexes from their surroundings by attaching biocompatible hydrophilic polymers 
like polyethylene glycol (PEG) [50-51].  
 
Assuming the polyplexes have avoided the enzymatic degradation in the blood stream 
and reached the vicinity of the cells, they then need to attach themselves to the cells’ 
surface in order to be internalized. The cationic surface charge of the polyplexes can bind 
to the negatively charged cell surface through electrostatic interactions. However, this 
process is highly non-specific and leads to binding with surfaces of random cells instead 
of just the target cell type. Research has been done to attach various targeting ligands to 
the surface of the polyplexes to increase their targeting abilities. For example, transferrin 
and folate have been used as ligands to target the over-expressed receptors on cancer 
cells’ surfaces to improve the efficiency of the non-viral gene delivery [52-53]. 
 
Due to their large size, the polyplexes cannot diffuse through cell membranes and must 
be internalized by a process called endocytosis, where the cell membrane forms a vesicle 
around the polyplexes and pinches off into the cytosol. Endocytosis is generally classified 
into two groups: phagocytosis, for taking up large particles, and pinocytosis, for taking up 
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smaller particles, fluid, and solutes. Phagocytosis occurs in a limited number of cell 
types, where pinocytosis occurs in virtually all cells and is one of the most important 
pathways in gene delivery.  
 
1.4.3 Endocytosis and Receptor-Specific Internalization 
There are four main types of pinocytosis: marcopinocytosis, clathrin-mediated 
endocytosis, caveolin-mediated endocytosis, and clathrin/caveolin-independent 
endocytosis (Fig 1.3). Each pathway will result in different sizes of vesicle and leads to 
different subsequent intracellular processes for the endocytosed polyplexes [54]. Once a 
non-viral gene delivery vector is internalized from the cell’s surface via pinocytosis, it 
will initially be located within either a caveosome or an early endosome, for caveolin-
mediated and clathrin-mediated pathways, respectively [55-56]. 
 
Clathrin-dependent endocytosis is a cellular uptake pathway associated with several 
receptors including transferrin receptor and clathrin-coated pits, a region of the 
membrane where the protein clathrin assembles on the intracellular surface of the cell 
membrane. When the polymeric vector is internalized by clathrin-dependent endocytosis, 
it is trafficked to clathrin-coated vesicles and subsequently moved to an acidified 
environment in early endosomes then lysosomes and degraded [57]. On the other hand, 
caveolin-dependent endocytosis is associated with receptors such as folate (or folic acid) 
receptor and lipid rafts, cholesterol-rich regions of the cell membrane where the protein 
caveolin is one of the main components, on the cell surface [58]. It has been suggested 
that the trafficking of polymer through caveolin-dependent endocytosis avoids an 
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acidified environment and lysosomal degradation [59]. However, the fate of the 
caveosome is not well established. Evidence has suggested that caveosomes may merge 
into clathrin-mediated pathway in the early endosome stage or be localized into recycling 
endosomes [60-63].  
 
1.4.4 Intracellular Barriers 
Regardless of uptake pathway, the ability of escaping from the endocytic vesicle is one of 
the most crucial factors that dictate the efficiency of a non-viral gene delivery system. 
For lipid gene delivery, it has been speculated that the cationic lipid mixes with the 
negatively charged lipids in the endosome, which causes a reduction in the lipid’s DNA 
condensation strength and leads to the release of the DNA into the cytosol [64]. Unlike 
lipids, certain cationic polymers, like PEI, have a completely different proposed 
mechanism, called the proton sponge effect, for escaping endosomes. In general, ATPase 
on the endosomal membrane actively transports protons into the early endosome to 
acidify the endosomal environment. Due to the high density of secondary and tertiary 
amines on the polymer with pKa values between physiological and lysosomal pH, proton 
sponge materials like PEI prevent the acidification of the endosome by absorbing the 
protons through the protonation of their own amine groups. As a result, the ATPase 
transports more protons into the endosome to try to reach the target acidic pH. To retain 
electroneutrality, an increased amount of counter ions, mainly chloride, are also 
transported into the endosome, leading to an increase in internal osmotic pressure, 
endosomal swelling, and eventual burst (Fig 1.4). The proton sponge hypothesis is 
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debated among scientific community and some have questioned the validity of the 
hypothesis [101-102]. 
 
After the polyplex escapes from the endosome, it must travel through the cytosol to reach 
the nuclear membrane. Studies have shown that passive diffusion is unlikely to be 
responsible for moving the polyplex to the nuclear membrane [65]. Based on fluorescent 
particle tracking experiments, microtubules and filaments appear to actively transport the 
polyplex through cytosol using molecular motors [66-67]. Drake et. al. have investigated 
the roles of microtubules and filaments in PEI gene delivery [103]. They have shown that 
the disruption of microfilaments and the depolymerization of microtubules led to 60-80% 
and 75% reduction in PEI gene delivery activity, respectively.   
 
One of the last intracellular trafficking barriers the polyplexes need to overcome after 
reaching the perinuclear space is to gain entrance to the nucleus and unpack the gene 
inside the nucleus [68-70]. There are two possible methods the polyplexes use for nuclear 
entry. The first method involves the polyplexes utilizing the nuclear pores on the 
membrane for entrance. There are thousands of nuclear pore complex (NPC), ~150 
nanometers in diameter, on the surface of the nuclear membrane that open or close 
depending on the presence of a nuclear localization signal (NLS) on the object trying to 
enter [71]. In their open state, the pores allow active transport of molecules with a 
diameter of ~26 nanometers, while in their closed state, the pores only allow molecules 
with diameters less than 9 nm to diffuse through [72]. As a result, research has been done 
to covalently attach NLS to DNA to induce the opening of the nuclear pores for active 
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transport of DNA, and potentially entire polyplexes, into the nucleus [73-74]. Some have 
shown increased gene delivery activity and others have shown there are no significant 
effects on gene delivery activity through NLS-DNA conjugation [104]. The second 
nuclear entry method involves polyplexes entering the nucleus through the breakdown of 
the nuclear envelope during mitosis. As the cells split into two daughter cells, the nuclear 
envelope breaks open and allows the negatively charged chromatin to interact with the 
cationic polyplexes and to competitively displace DNA from the cationic polymers. The 
displaced DNA is then trapped inside the nucleus as the nuclear envelope is reconstructed 
after mitosis, allowing the DNA to be transcribed inside the host’s nucleus. Studies have 
shown that gene delivery efficiency increases when cells are dividing [75]. 
 
With the understanding of the extracellular and intracellular barriers involved with non-
viral gene delivery in mind, it is important to choose materials that condense and protect 
DNA, are able to be internalized by cells, escape the endosome, and carry the DNA to the 
nucleus. As mentioned earlier, two of the most heavily researched materials that fulfill all 
of these requirements are cationic lipids and polymers. 
 
1.4.5 Lipid-Mediated Gene Delivery 
Cationic lipids, like 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 
dioleoylphophatidylethanolamine (DOPE), and N-[1-dioleyloxy)propyl]-N,N,N-
trimethylammonium (DOTMA), are commonly used to complex with DNA to form 
lipoplexes for lipid-based gene delivery [76]. Cationic lipids consist of three major 
components: a hydrophobic lipid anchor group, a linker group, and a positively charged 
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headgroup. The hydrophobic lipid anchor helps the formation of liposomes, the 
headgroup condenses the DNA, and the linker group dictates the stability of the lipids. 
For example, the ether linker between headgroup and acyl chain of DOTMA is more 
stable than the labile ester linkage of DOTAP [77]. In additional to the property of the 
linker group, the valence of the lipid headgroup has also been shown to affect the lipid’s 
gene transfer capability [78-79]. The overall transfection efficiency of lipoplexes is low 
compared to viruses due to the intracellular barriers mentioned above. . Researchers have 
explored the addition of helper lipids and targeting ligands to lipoplexes to facilitate 
endosomal escape and to increase cell targeting and uptake. Both strategies have shown 
an improvement in transfection efficiency [80-82]. 
 
1.4.6 Polymeric Gene Delivery 
Cationic polymers, like poly-l-lysine (PLL), polyamidoamine (PAMAM), 
polyethylenimine (PEI), poly(β-amino ester)s, and poly(2-(dimethylamino)ethyl 
methacrylate) (pDMAEMA), are heavily studied as potential gene delivery vehicles due 
to their capability to condense negatively charged DNA and protect the DNA from its 
cellular surroundings. Poly(β-amino ester)s have been shown to mediate gene transfer 
better than Lipofectamine 2000, a commercial lipid-based gene delivery reagent [83]. 
However, unlike poly(β-amino ester)s, other cationic polymers are plagued by either low 
transfection efficiency (PLL, pDMAEMA) or high toxicity (PEI and PAMAM), making 
them non-ideal gene delivery vectors [84-86]. Similar to lipoplex gene delivery, many 
researchers have investigated different synthesis strategies to increase the efficiency of 
these non-viral vectors via aiding the endosomal escape, lowering the toxicity, or 
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improving cell targeting. For example, melittin, an endosomolytic peptide, is added onto 
PLL polyplexes to aid their endosomal escape capability [87]. Polyethylene glycol (PEG) 
has been added onto PAMAM to shield the positive surface charge from the cells, 
reducing toxicity and increasing efficiency [88].  
 
1.5 Polyethylenimine and PEI Derivatives 
 
1.5.1 PEI 
Compared to other cationic polymers, PEI is one of the most commonly used in gene 
delivery. It is inexpensive and commercially available in linear or branched form in 
different molecular weight ranging from 0.8 to 1000 kDa. It has high primary, secondary, 
and tertiary amine densities, which allows easy functionalization with ligands to enhance 
its cell targeting and uptake [89-90]. In addition to its ability to condense DNA through 
electrostatic interaction, PEI is a proton-sponge material [91], which is believed to allow 
PEI polyplexes to escape endosomes and results in improved gene delivery activity. The 
25-kDa unmodified form of PEI has been shown to exhibit high transfection efficiency in 
vitro but its high toxicity prevents it from being used clinically. As a result, it is 
commonly used as a transfection reference standard to compare with other newly 
synthesized gene delivery vectors. Much research has been done to reduce the toxicity of 
PEI while improving its efficiency and cellular uptake by modifying or functionalizing 
the polymer’s structure. One of the main strategies being used to achieve this goal is to 
cross-link low molecular weight PEI, which is relatively non-toxic, with a degradable 
cross-linker as described below.  
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1.5.2 Biodegradable PEI 
In general, gene delivery efficiency is directly related to the molecular weight of PEI, 
while toxicity is inversely related. Gosselin et al. concluded that 25 kDa PEI displays 
gene delivery efficiency 50-fold higher than 800 Da PEI but reduces cell viability by 
more than half [92]. Since material toxicity should be one of the major considerations in 
any gene delivery vector’s design, researchers have explored various alternatives to 
temporarily increase the molecular weight of low molecular weight cationic polymers. 
The resulting polymers would condense DNA and possess gene delivery efficiency 
similar to their high molecular weight counterparts and degrade into a less toxic low 
molecular weight version of the polymers inside the cells. One common approach is to 
insert a degradable cross-link between low molecular weight cationic polymer molecules. 
Many syntheses have been investigated to cross-link polymers using different cross-
linker-polymer combinations.  
 
One of the specific cross-linking strategies that have been commonly used in synthesizing 
degradable polycations is the Michael addition of amines to acrylate groups. Lynn et al. 
screened a library of 140 diacrylate cross-linked amine polymers, showing some specific 
combinations of diacrylates and amine monomers with promising transgene expression 
[93]. Since then, many researchers have studied further the gene delivery properties of 
those polymers reported by Lynn et al. Forrest et al. detailed the synthesis of degradable 
PEI derivative by cross-linking 800 Da PEI with 1,3-butanediol diacrylate and 1,6-
hexanediol diacrylate. The resulting polycations showed several fold increase in 
transfection efficiency compared to 25 kDa PEI, and are essentially non-toxic [94]. To 
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further the study of Forrest et al., Shum et al. [95] incorporated polymer supported 
PVP(Fe(III)) to catalyze the synthesis of degradable PEI by cross-linking 800 Da PEI 
with 1,6-hexanediol diacrylate (Fig 1.5). The resulting reaction produced a wider MW 
range of degradable PEIs and the polymers exhibit higher transfection efficiency and 
cellular uptake, while showing minimal toxicity, compared to unmodified 25 kDa PEI in 
HeLa and MDA-MB-231 cell lines. 
 
1.5.3 Acetylated PEI 
Another strategy researchers have explored to make PEI more efficient as a gene delivery 
vector is to control the electrostatic interaction between positively charged PEI and 
negatively charged DNA. Forrest et al. reduced the attraction between 25 kDa branched 
PEI and DNA though partial acetylation of primary and secondary amines of PEI and 
converted them into secondary and tertiary amides, respectively [96] (Fig 1.6). By 
eliminating the number of amine groups available in PEI, acetylation lowered the cationic 
charge of PEI and enhanced the dissociation of PEI/DNA polyplexes in physiological 
condition. Utilizing partially acetylated PEIs, Forrest et al. showed that the in vitro gene 
delivery activity improved almost 21-fold for 42% acetylation of PEI’s primary amines. 
To further Forrest et al. study, Gabrielson et al. synthesized a full range of acetylated PEI 
and investigated their gene delivery activity and cellular uptake [97]. The acetylated PEIs 
have shown 30-fold (up to 60 fold, depending on cell line) increase in gene delivery 
activity and almost 3-fold increase in cellular uptake compared to 25kDa branched PEI. 
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1.6 Concluding Remarks 
Gene therapy has the potential to treat many human diseases. With the advance of the 
Human Genome Project and the improved understanding of the genetic component of 
certain illnesses, gene therapy is the next promising method in medicine to treat the root 
cause of various illnesses. Viral vectors have shown great efficacy in delivery of genetic 
material both in vitro and in vivo and are being investigated in many clinical trials in the 
U.S. However, with the inherent cost of virus production and risks involved in using 
viruses, non-viral vectors should be investigated as an alternative. The commercially 
available cationic polymer PEI has shown great promises in in vitro gene delivery study. 
However, its efficacy is still lacking compared to viral vectors and its cytotoxicity is a 
concern. As a result, in this study, we aim to elucidate the design criteria for effective PEI 
gene delivery by investigating the effect of endocytic uptake pathway, namely clathrin- 
and caveolin-dependent endocytoses, on PEI and its derivatives gene delivery activity in 
vitro and in vivo.  
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1.7 Tables and Figures 
 
Figure 1.1: Commonly used cationic polymers and lipid for non-viral gene delivery [98] 
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Figure 1.2: Cellular mechanisms involved in non-viral gene delivery. Complexes must 
overcome many barriers, including cell surface binding, endocytosis, exocytosis, 
lysosomes, endosomes, nuclear entry, and DNA unpackaging, in order to carry the 
therapeutic gene into the host’s nucleus for transfection [91] 
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Table 1.1: Advantages and disadvantages of viral and non-viral vectors for gene therapy 
 
Viruses Non-Viral Vectors 
Immunogenicity High Low 
Pathogenicity High None 
Oncogenicity High None 
Toxicity Low High 
Efficiency High Poor 
Cell Targeting Ability Difficult to Adjust Easy to Modify 
Availability Low/Custom Made Readily Available 
Cost Expensive Cheap 
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Figure 1.3: A simplified schematic summarizing various endocytic pathways into cells. 
Retrieved and modified from Mayor et al. [99] 
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Figure 1.4: Schematic of endosomal escape through proton sponge mechanism [91] 
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Figure 1.5: Synthesis of biodegradable PEI derivatives. 800 Da PEI is cross-linked with 
1,6-hexanediol diacrylate in methanol overnight at 60
o
C, catalyzed by PVP(Fe(III)) 
heterogenous catalyst. The diacrylate groups can react with primary and secondary 
amines of the PEI. [95] 
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Figure 1.6: Synthesis of acetylated PEI derivatives. Primary and sceondary amines from 
25 kDa PEI reacted with acetic anhydride to generate secondary amides and tertiary 
amides in methanol for four and a half hour at 65
o
C. [97, 100] 
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Chapter 2 
Efficacy of PEI Gene Delivery Through Clathrin- and Caveolin-
Dependent Endocytosis In HeLa and MDA-MB-231 Cells 
 
2.1 Introduction 
Endocytosis is the primary process used by most cell types to internalize biomolecules or 
other cargo such as non-viral vectors in gene delivery through engulfment on the cell 
surface. The best characterized endocytosis mechanisms are clathrin- and caveolin-
dependent endocytosis, clathrin- and caveolin-independent endocytosis, 
macropinocytosis, and phagocytosis [1-2]. These pathways all involve the formation of 
vesicles of different sizes to engulf cargo such as non-viral vectors. However, as 
mentioned in Chapter 1, the cellular fate of vectors internalized through each type of 
endocytosis varies drastically. 
 
Clathrin-dependent endocytosis is a well-studied process that occurs in all mammalian 
cells. Cargo is internalized through a clathrin-coated pit, a small vesicle that is 
surrounded by the protein clathrin and pinches off to form an early endosome. Early 
endosomes mature into late endosomes and subsequently fuse with enzyme-filled vesicles 
from the Golgi to form lysosomes.  This process is associated with a rapid acidification 
from neutral pH to pH ~6 in early endosomes and then pH 4.5-5 in late endosomes and 
lysosomes. As a result, cargo internalized via this pathway is trafficked to the degradative 
environment of the lysosome. However, specific receptors and their ligands can also be 
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trafficked to various cellular destinations throughout this process, including recycling 
back to cell surface. 
 
Caveolin-dependent endocytosis is similar to clathrin-dependent endocytosis; it involves 
formation of a vesicle in a cell membrane domain that is rich in cholesterol and the 
protein caveolin. When the vesicle pinches off from the cell membrane, it is then slowly 
trafficked to a neutral pH vesicle called a caveosome. The main differences between 
caveosomes and clathrin-coated vesicles are 1) caveosomes are generally smaller, 2) 
caveosomes are not acidified throughout the process, and 3) caveosomes are not routed to 
lysosomes [7-9]. 
 
Clathrin- and caveolin-independent endocytosis, along with macropinocytosis, are also 
commonly studied endocytic processes. In this project, they are treated as either controls 
to measure against or processes to be avoided. Phagocytosis is a process that happens 
only in a few specialized cells to internalize large particles and cell debris. As a result, 
phagocytosis is generally regarded as a pathway not important to non-viral gene delivery.   
 
Many cancer cells overexpress the receptors for the ligands transferrin and folate. 
Transferrin and folate receptors are associated with clathrin- and caveolin-dependent 
endocytosis, respectively [3-6]. One can conjugate the corresponding ligand to a gene 
delivery vehicle to increase the specificity of the vehicle and to improve gene delivery 
effectiveness by directing the vehicle toward a particular, potentially more efficient 
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endocytosis pathway. Transferrin and folate have often been conjugated to unmodified 
25kDa PEI for this purpose [10-11]. 
 
Small molecule drugs allow selective inhibition of endocytic pathways to study the effect 
of endocytic uptake on PEI-mediated gene delivery [22]. The four small molecule drugs 
used in our studies to selectively inhibit either clathrin- or caveolin-dependent 
endocytosis are genistein, methyl-β-cyclodextrin (mβCD), chlorpromazine, and 
amantadine. Genistein prevents the phosphorylation of caveolin, resulting in the 
inhibition of caveosome formation and arrest of the caveolin-dependent pathway [12]. 
mβCD binds and sequesters cholesterol in the lipid-rich domains on the cell surface and 
prevents the formation of caveolae [13]. Chlorpromazine prevents clathrin-dependent 
endocytosis by dissociating the clathrin-coated pit formation from the plasma membrane 
at the ligand binding site [14]. Similarly, amantadine inhibits clathrin-dependent 
endocytosis by blocking the budding of clathrin-coated vesicles [15]. 
 
In this chapter, we report the results of gene delivery studies performed with HeLa 
(human cervical adenocarcinoma cells) and MDA-MB-231 (human breast 
adenocarcinoma) using unmodified 25 kDa branched PEI in the presence of small 
molecule drugs. In addition, PEI was conjugated with transferrin or folate to target 
clathrin- or caveolin-dependent endocytic pathways, respectively, and then used for gene 
delivery experiments in the presence of competitive ligands and small molecule drugs in 
order to investigate the effect of uptake pathway on PEI gene delivery. Overall, the 
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decrease in gene delivery activity upon inhibiting a specific endocytic pathway indicates 
that the corresponding pathway is involved in efficient gene delivery, and vice versa. 
 
2.2  Results 
 
2.2.1 Small Molecule Drug Toxicity and PEI Transfection  
As mentioned previously, four small molecule drugs were used in this study to 
specifically inhibit either clathrin- or caveolin- dependent endocytosis. However, prior to 
using such drugs for gene delivery studies, the cytotoxicity of each drug for the two cell 
lines used in this study, HeLa and MDA-MB-231, needed quantification (Figure 2.1.A-
2.1.D). For HeLa, all genistein, chlorpromazine, and amantadine concentrations 
maintained over 80% cell viability in the tested range, while mβCD reached 50% cell 
viability at 10 mg/mL mβCD. However, MDA-MB-231 cells were more sensitive to the 
drugs than HeLa. MDA-MB-231 cells reached 50% cell viability at 10 mg/mL, 7 µg/mL, 
1.8 mM for mβCD, chlorpromazine, and amantadine, respectively, and maintained over 
90% cell viability for genistein in the tested range.  Based on these data and previous 
studies, the concentrations of 50 µg/mL genistein, 2 mg/mL mβCD, 5 µg/mL 
chlorpromazine, and 1 mM amantadine were used for gene delivery study to avoid 
significant drug cytotoxicity and providing inhibition of the targeted uptake mechanism 
[19,23]. 
 
Besides drug cytotoxicity, it is also important to measure the inherent cytotoxicity of 
unmodified 25 kDa PEI for the two cell lines used in this study (Figure 2.2). Both HeLa 
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and MDA-MB-231 cells reached 50% cell viability at approximately 10 µg/mL PEI, 
roughly equal to 10:1 PEI/DNA weight-to-weight ratio (w/w ratio). As a result of such 
high PEI cytotoxicity, lower w/w ratios were tested in the presence of drugs to determine 
the optimal w/w ratio to be used for the rest of the study (Figure 2.3.A and 2.3.B). The 
data were normalized to no drug control at each w/w ratio. One can see the inhibition of 
clathrin-dependent endocytosis (chlorpromazine and amantadine) improved the gene 
delivery activity of unmodified PEI by three- to five-fold in HeLa and approximately 
two-fold in MDA-MB-231 at 4:1 w/w ratio. In the presence of genistein and mβCD, 
which inhibit the formation of caveolae, gene delivery effectiveness was drastically 
reduced in both HeLa and MDA-MB-231 at tested w/w ratios. Because of the drug 
effects on unmodified PEI gene delivery performance, 4:1 PEI/DNA w/w ratio was 
determined to be optimal for drug inhibition gene delivery studies and was used for the 
rest of the studies unless specified otherwise.  
 
2.2.2 PEI Polyplex Sizing and Zeta Potential 
For polyplexes to be efficiently endocytosed, it is critical that the cationic polymer is able 
to form nanoscale complexes with plasmid DNA. Dynamic light scattering (DLS) was 
used to determine the size of the polyplexes immediately after polyplex formation at each 
PEI/DNA w/w ratio, and again after two hours incubation at 37°C (Figure 2.4). There is 
no significant size difference for PEI polyplexes at tested w/w ratio before and after 
incubation. All polyplexes’ effective diameters were less than 400 nm. There is a trend of 
decreasing size as the w/w ratio increases, which indicates that the more PEI used to form 
polyplexes, the more compact the polyplexes were. Another way to characterize 
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polyplexes is to measure their zeta potential. Similar to DLS measurement, PEI 
polyplexes’ zeta potential was measured before and after two hours of 37°C incubation 
(Figure 2.5). There is no significant zeta potential difference before and after the 
incubation. Zeta potential of 1:1 w/w ratio polyplexes was ~ 30 mV, and 2:1 and 4:1 
polyplexes was ~ 25 mV. 
 
2.2.3 Transferrin- and Folate-PEI Transfection and Free Ligand Competitive 
Inhibition 
The synthesis of cell receptor targeting PEI involved the conjugation of unmodified 25 
kDa branched PEI with transferrin (Tf) protein or folate (Fol). For Tf-PEI, transferrin was 
first reacted with Sulfo-KMUS and conjugated with thiolated unmodified PEI (Figure 
2.13). Through Ninhydrin Assay and BCA Total Protein Assay characterization, the 
labeling density of transferrin and PEI was roughly one transferrin per PEI (100% 
labeling). For Fol-PEI, folate was first reacted with NHS crosslinker and, subsequently 
conjugated with unmodified PEI at folate-to-PEI molar ratio of 0.8, 5, and 9 (Figure 
2.14). 
 
Both HeLa and MDA-MB-231 cells were transfected with polyplexes comprising various 
ratios of Tf-PEI and unmodified PEI to study the effect of transferrin receptor targeting 
on PEI gene delivery activity (Figure 2.6.A and 2.6.B). Compared to unmodified PEI, 
Tf-PEI shows two- to six-fold increase in gene delivery activity, except for 100% Tf-PEI 
in both cell lines and 10% Tf-PEI in MDA-MB-231. This indicates that transferrin 
receptor targeting improved gene delivery efficacy in both HeLa and MDA-MB-231. 
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Similar studies were performed using 0.8, 5, and 9 molar ratios Fol-PEI to form 
polyplexes and transfect both cell lines (Figure 2.7.A and 2.7.B). Compared to 
unmodified PEI, only 0.8 Fol-PEI showed two- to six-fold increase in gene delivery 
activity in HeLa and MDA-MB-231 cells. The 5 and 9 molar ratios Fol-PEI showed 
either no difference or reduced gene delivery efficacy, which demonstrates that there is a 
critical amount of folate-to-PEI labeling in order to observe the effect of folate receptor 
targeting PEI gene delivery. 
 
Prior to using receptor-targeting PEIs for transfection study in the presence of drugs, it is 
important to ensure the receptor-targeting PEI polyplexes indeed bound to the targeted 
receptor. One of the methods to determine if the receptor-targeting PEIs, Tf-PEI and Fol-
PEI, were internalized through their respective targeted receptors was to transfect HeLa 
and MDA-MB-231 cells with receptor-targeting PEIs in the presence of competitive 
ligands (Figure 2.8.A, 2.8.B, 2.9.A, and 2.9.B). For HeLa cells, the presence of free 
transferrin reduced 25% Tf-PEI gene delivery activity by 40% and decreased 
approximately 15% of unmodified PEI at high transferrin concentration. Similar trends 
were observed in MDA-MB-231 cells, where free transferrin ligand reduced gene 
delivery of unmodified PEI and 25% Tf-PEI by 20% and 40%, respectively. The effect of 
folate on gene delivery was more prominent than transferrin. In the presence of folate 
ligand, the gene delivery was decreased by 40% and 90% for unmodified PEI and 0.8 
Fol-PEI, respectively, in HeLa. In MDA-MB-231, there was no statistical difference for 
unmodified PEI transfection between the absence and presence of folate. However, for 
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0.8 Fol-PEI, the gene delivery activity was reduced by 40% and 75% at 500 µM and 
1000 µM of free folate ligand, respectively, in MDA-MB-231. 
 
2.2.4 Cell-Targeting PEI Transfection in the Presence of Pathway Inhibiting Drugs 
To further investigate the effect of receptor-mediated uptake and clathrin- and caveolin-
dependent endocytosis, Tf-PEIs and Fol-PEIs were used to transfect HeLa and MDA-
MB-231 in the presence of pathway inhibiting drugs. In this study, 4:1 polymer/DNA 
w/w ratio was used because only at 4:1 w/w ratio were there statistically significant 
differences between control, clathrin-inhibiting, and caveolin-inhibiting drug data for 
both HeLa and MDA-MB-231 cells, as mentioned previously. Ten percent and 25% Tf-
PEI and 0.8, 5, and 9 Fol-PEI were used in this study (Figure 2.10.A and 2.10.B). In the 
presence of mβCD or genistein, in both HeLa and MBA-MB-231, the gene delivery 
activity of all six forms of PEI was reduced compared to the no-drug control. When 
clathrin-dependent endocytosis was inhibited by chlorpromazine or amantadine, all PEIs 
showed improvement in gene delivery activity, approximately one- to two-fold, in both 
cell lines. 
 
2.2.5 Transferrin- and Folate-PEI/DNA Polyplex Sizing and Zeta Potential 
Similar to unmodified PEI polyplexes, Tf-PEI and Fol-PEI polyplexes were characterized 
using dynamic light scattering and zetasizer (Figure 2.11 and 2.12). Ten percent Tf-PEI 
polyplexes had the largest effective diameter compared to unmodified PEI and other 
labeled PEI polyplexes. It is likely due to the size difference between transferrin protein 
(~80 kDa) and PEI (25 kDa). Unfortunately, 25% Tf-PEI polyplexes were out of the 
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measurement range of the instrument, and no sizing data could be reported. However, 
25% Tf-PEI polyplexes are expected to be slightly larger than 10% Tf-PEI polyplexes in 
effective diameter due to the additional transferrin protein present. Besides 10% Tf-PEI, 
the unmodified PEI and Fol-PEI polyplexes had effective diameter ~ 100 nm before and 
after 37°C incubation. Unmodified PEI polyplexes showed higher zeta potential (~25mV) 
than most labeled PEI polyplexes before and after incubation, except 0.8 Fol-PEI. This 
trend is expected as targeting ligand conjugation converted primary and secondary 
amines to secondary and tertiary amide groups with lower pKa, which led to reduced zeta 
potential. Overall, all tested polyplexes’ zeta potential was over 15mV, which suggests 
the suspensions were stable.   
 
2.3 Discussion 
Successful non-viral gene delivery is generally believed to be dependent on cell receptor 
related endocytosis [16-17]. Previous studies have investigated the effects of various 
endocytic uptake pathways using different non-viral vectors in vitro [18-20]. In this 
dissertation, we have sought to investigate the effect of clathrin- and caveolin- dependent 
endocytosis on PEI gene delivery in cancer cells in vivo (see Chapter 5). To this end, it 
is crucial first to quantify the effects of those two pathways on in vitro PEI gene delivery 
in the two cell lines, HeLa and MDA-MB-231, used in this project. 
 
To investigate the effect of clathrin- and caveolin- dependent endocytosis on PEI gene 
delivery, four small molecule drugs were chosen to specifically inhibit the two pathways. 
The cytotoxicity of each drug was measured by MTT assay and an optimal concentration 
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to be used for transfection was determined (Figure 2.1.A-2.1.D). When HeLa and MDA-
MB-231 cells were transfected with unmodified 25 kDa PEI in the presence clathrin-
dependent endocytosis inhibiting drugs (chlorpromazine and amantadine), the gene 
delivery activity of PEI polyplexes increased by two- to five-fold at 4:1 polymer:DNA 
w/w ratio (Figure 2.3.A and 2.3.B). This suggests the effect of drug-induced endocytic 
pathway inhibition is somewhat dependent on the polymer/DNA ratio. A critical amount 
of polymeric vector must be used in order to observe the difference in gene delivery 
activity when an uptake pathway is inhibited. More importantly, the data also suggest that 
clathrin-dependent endocytosis is not critical to PEI-mediated gene delivery and leads to 
inefficient gene delivery. However, in the presence of caveolin-dependent endocytosis 
inhibiting drugs (genistein and amantadine), the gene delivery activity of PEI polyplexes 
was reduced by 50-90% at tested w/w ratios. This result demonstrates that caveolin-
dependent endocytosis is important to efficient PEI-mediated gene delivery in both 
MDA-MB-231 and HeLa cells, which is in good agreement with the clathrin-inhibiting 
drug results and also previous studies demonstrating similar trends in HeLa [19].  
 
One of the likely explanations for why 4:1 w/w is the optimal transfection polymer/DNA 
w/w ratio for drug inhibition study was the size difference between 1:1 and 4:1 w/w 
ratios (Figure 2.4).  Prior to and after the incubation, the 1:1 w/w ratio polyplexes were 
three and two-and-a-half times, respectively, larger than 4:1 w/w ratio polyplexes. The 
difference in size between the polyplexes indicates that a particular size must be reached 
in order for the effect of cell receptor endocytosis to be observed.  Unlike the huge 
polyplex size difference, the zeta potential of the polyplexes made with different w/w 
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ratios only differed by 5mV and could not contribute to the explanation why 4:1 w/w 
ratio was the optimal transfection ratio for pathway drug inhibition study (Figure 2.5). 
 
Receptor-targeting PEIs were synthesized using transferrin protein and folate. For Tf-PEI 
polyplexes, 100% Tf-labeled PEI was mixed with different amount of unlabeled PEI to 
form desired % Tf-PEI polyplexes. When various % of Tf-PEI was used to transfect 
HeLa and MDA-MB-231, one can see that the presence of a certain amount of Tf-PEI 
polyplexes mixed with unmodified PEI polyplexes enhanced the gene delivery activity by 
two- to seven-fold, depending on the cell line, compared to unmodified PEI (Figure 
2.6.A-2.6.B). This could be explained by the fact that the presence of some Tf-PEI 
polyplexes occupied the transferrin receptors on the cell surfaces and forced the 
unmodified PEI polyplexes to go through other uptake pathways, similar to the effect of 
clathrin-dependent endocytosis inhibiting drugs. This explanation is confirmed by the 
fact that gene delivery activity of 100% Tf-PEI polyplexes shows no significant 
difference compared to 100% unmodified PEI polyplexes. For Fol-PEI polyplexes, unlike 
Tf-PEI, all the polyplexes were formed with PEI conjugated with the indicated molar 
ratio of folate. When the two cell lines were transfected with 0.8 Fol-PEI, the gene 
delivery activity was improved by half- to six-fold compared to unmodified PEI (Figure 
2.7.A-2.7.B). This result is in good agreement with the drug study results where we 
concluded that caveolin-dependent endocytosis is critical to successful gene delivery. 
However, the gene delivery of polyplexes containing higher folate labeling ratios displays 
either no improvement or reduced activity, which is unexpected. This trend is likely due 
to the increased amount of conjugated folate present at higher folate-PEI ratio occupying 
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all the folate receptors and thus retarding caveolin-dependent endocytosis, resulting in 
less efficient gene delivery. The overall result indicates that a crucial folate labeling 
density for folate-targeting PEI is required in order for the enhancement of caveolin-
dependent endocytosis to be observable.  
 
To demonstrate that the targeted PEIs were trafficked through the intended cell surface 
receptors, a free ligand competitive assay was used to illustrate the inhibition effect of 
free ligand on receptor-targeting PEI gene delivery performance (Figure 2.8.A, 2.8.B., 
2.9.A, and 2.9.B). For both HeLa and MDA-MB-231 cells, in the presence of free 
transferrin, the gene delivery activity of 25% Tf-PEI was reduced by ~40% compared to 
the absence of transferrin, which shows that the free ligand has partially inhibited the 
25% Tf-PEI transfection. Similar trend was observed when HeLa and MDA-MB-231 
cells were transfected with 0.8 Fol-PEI polyplexes in the presence of free folate. In HeLa, 
the gene delivery activity of 0.8 Fol-PEI was drastically reduced by ~90%; and in MDA-
MB-231, the gene delivery activity was decreased by 40% and 80% in the presence of 
500 µM and 1000 µM of free folate, respectively. The negative impact of the competitive 
ligand on targeted PEI polyplexes demonstrates that Tf-PEI and Fol-PEI were indeed 
targeted and trafficked through their respective cell receptors.  
 
By combining the inhibitory effect of small molecule drugs and the cell-receptor-
targeting capabilities of Tf-PEI and Fol-PEI, one can quantify the effect of endocytic 
uptake pathway on PEI gene delivery (Figure 2.10.A-2.10.B). When HeLa and MDA-
MB-231 cells were transfected with unmodified PEI, Tf-PEI, and Fol-PEI, two overall 
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trends were observed: 1) in the presence of caveolin inhibiting drugs (genistein and 
mβCD), the gene delivery activities of all the polyplexes tested were drastically reduced 
by 50-90%; and 2) in the presence of clathrin inhibiting drugs (chlorpromazine and 
amantadine), the gene delivery performances of all the polyplexes tested were enhanced 
by one- to two-fold. These results suggest that clathrin-dependent endocytosis does not 
contribute to successful PEI-mediated gene delivery as much as caveolin-dependent 
endocytosis does. All the polyplexes investigated in this study were characterized using 
DLS and Zetasizer (Figure 2.11-2.12). Unmodified PEI and Fol-PEI polyplexes’ 
effective diameters were ~100 nm, while Tf-PEI polyplexes’ effective diameter was 
significantly larger due to the presence of the transferrin protein. In term of zeta potential, 
all polyplexes’ zeta potential were in the range of 15-25 mV and no clear trend was 
observed.  
 
In conclusion, we have demonstrated the effect of endocytic uptake pathway on 
unmodified PEI and cell-receptor-targeting PEIs gene delivery. The results reported here 
suggest that caveolin-dependent endocytosis contributes to successful gene delivery in 
both HeLa and MDA-MB-231 cells, while clathrin-dependent endocytosis does not.  
 
2.4 Materials and Methods 
 
2.4.1 Cells and Plasmids 
The MDA-MB-231 human breast carcinoma cell line was purchased from the American 
Type Culture Collection (Manassas, VA). The HeLa human cervical carcinoma cell line 
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was a gift from Dr. Sandra McMasters (University of Illinois, Urbana, IL). Cells were 
cultured according to their ATCC protocols at 37 
o
C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM). The growth medium was supplemented with 10% fetal bovine 
serum (FBS) and 10% penicillin-streptomycin. The 5.3-kilobase expression vector pGL3 
(Promega, Madison, WI), coding for firefly luciferase gene driven by the SV40 promoter 
and enhancer, was purchased from Elim Biopharm (Hayward, CA) and used without 
further purification. 
 
2.4.2 Additional Chemicals 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless specified 
otherwise. Sulfo-KMUS, 2-iminothiolane, and BCA Protein Assays were purchased from 
Thermo Fisher Scientific (Rockford, IL). PD-10 desalting columns were obtained from 
GE Healthcare (Pittsburgh, PA). Amicon 100,000 MWCO centrifugal filters were 
purchased from Millipore (Billerica, MA). 
 
2.4.3 Transferrin- and Folate- PEI Syntheses 
Transferrin-PEI (Tf-PEI) was synthesized by using the heterobifunctional crosslinker 
sulfo-KMUS to conjugate unmodified 25-kDa branched PEI with human apo-transferrin. 
Briefly, PEI was first thiolated with 2-iminothiolane in 2 mL of PBS, containing 5 mM 
EDTA, by reacting overnight and, subsequently, purified by PD-10 desalting column. In 
parallel, primary amines of human apo-transferrin were conjugated with sulfo-KMUS 
overnight to generate a thiol-reactive form of transferrin, and the reaction product was 
purified by PD-10 desalting column. To quantify the total amount of thiolated PEI and 
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thiol-reactive transferrin protein resulting from the two reactions, Ninhydrin Assay and 
BCA Protein Assay were used, respectively. Approximately 1:1 molar ratio of thiolated 
PEI and thiol-reactive transferrin were allowed to react overnight. The 100-kDa final 
product was separated from the unreacted species using an Amicon 100,000 MWCO 
centrifugal filter. The concentrations of PEI and transferrin protein of the conjugated 
sample were measured by Ninhydrin Assay and BCA Protein Assay, respectively. The 
final PEI-transferrin conjugate was used without further purification (Figure 2.13).  
 
Folate-PEI was synthesized according to the reaction of Guo et al. [21]. Briefly,  
folate (folic acid) was dissolved in DMSO and reacted with 1:1 molar excess of NHS and 
N,N’-dicyclohexylcarbodiimide (DCC) overnight. The next day, NHS-folate product was 
collected by filtration. The NHS-folate was then reacted with 25kDa branched PEI at 
various molar ratios’ excess overnight.  The final PEI-folate products were purified using 
a PD-10 desalting column, and the folate-PEI ratio was quantified by Ninhydrin Assay 
and ultraviolet absorption at 363nm, respectively (Figure 2.14). 
 
2.4.4 In Vitro Transfection 
Cells (MDA-MB-231 or HeLa) were cultured in DMEM with 10% fetal bovine serum 
and 10% penicillin-streptomycin. In a 24-well plate, 8x10
4
 cells/well were seeded in 
growth medium with serum 24 h before transfection. On the day of transfection, growth 
medium was replaced with fresh serum-free DMEM. For transfections performed in the 
presence of caveolae inhibitors (50 µg/mL genistein, 2 mg/mL methyl-β-cyclodextrin) or 
clathrin inhibitors (5 µg/mL chlorpromazine, 1 mM amantadine), the growth medium was 
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replaced with folate-free, serum-free DMEM containing the desired drug one hour prior 
to transfection. Before transfection, 50 µL of polyplexes in a solution of 120 mM NaCl 
and 16 mM PIPES at pH 7.2 were formed with 0.5 µg pGL3 and various amount of 
polymer to achieve desired weight-to-weight ratio. The polyplexes were incubated at 
room temperature for 15 min and then added into each well (50 µL polyplexes/well). 
Two hours post-transfection, DMEM was replaced with fresh growth medium with serum 
and incubated overnight. Twenty-four hours post-transfection, luciferase expression was 
determined using the Promega Luciferase Assay System (Promega, Madison, WI), which 
reports expression levels as relative light units (RLU) as measured on the Lumat L 9507 
luminometer (Berthold, GmbH, Germany). Each experiment was performed in 
quadruplicate. Luciferase expression results (RLUs) were normalized to total cell protein 
amount using BCA Protein Assay. 
 
2.4.5 Free Ligand Competitive Inhibition 
Polyplexes were prepared and cells were seeded in a 24-well plate format as described 
previously. Thirty minutes prior to transfection, the growth medium was replaced with 
folate-free, serum-free DMEM containing the targeted concentrations of either free 
transferrin or folate, and then the plate was incubated at 4 °C. At the time of transfection, 
50 µL polyplexes/well was added into each well and the plates were incubated at 37 °C. 
One and a half hours post-transfection, the folate-free, serum-free DMEM was replaced 
with fresh growth medium with serum and incubated overnight. Twenty-four hours post-
transfection, luciferase expression and total protein concentration were measured. 
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2.4.6 Cytotoxicity Measurement 
The cytotoxicity of polymers on the MDA-MB-231 and HeLa cells was characterized 
using the CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT) (Promega) 
according to the manufacturer’s protocol. Briefly, 8x10
3
 cells/well were seeded in a 96-
well microplate in growth medium containing 10% FBS and incubated at 37
o
C and 5% 
CO2 overnight. Approximately 24 h after seeding, the medium was replaced with folate 
free, serum-free DMEM, and various amounts of drug or polymer was added to the cells 
to achieve target concentrations. Following a 3 h incubation period at 37
o
C and 5% CO2, 
the medium was replaced with fresh serum-containing medium and incubated for another 
24 h, after which 15 µL of the Dye Solution was added into each well, and cells were 
incubated for another 4 h. After incubation, 100 µL of the Solubilization Solution/Stop 
Mix was added into each well and incubated for another 1 h. Afterward, the absorbance 
at 570 nm, with a reference wavelength of 650 nm, was measured using an absorbance 
plate reader. The absorbance of medium only was subtracted from the viable cell 
absorbance and normalized to the absorbance reading of cells with no drug/polymer 
present. Each drug/polymer and drug/polymer concentration were tested five times in 
each experiment.  
 
2.4.7 Dynamic Light Scattering and Zeta Potential 
One microgram of DNA was diluted into 200 µL of a solution of 120 mM NaCl and 16 
mM PIPES at pH 7.2. Polymer was dissolved in double distilled water. The amount of 
54 
 
polymer sample used was determined by the transfection ratio and diluted into 200 µL of 
120 mM NaCl, 16 mM PIPES at pH 7.2, and was added to the 200 µL DNA/PIPES 
solution to form the desired polymer and DNA weight–to-weight ratio polyplexes. The 
polyplexes were incubated at room temperature for 15 min, and double distilled water 
was added to reach a final sample volume of 1 mL. The polyplexes’ size and zeta 
potential were measured by Malvern Instruments’ Zetasizer Nano ZS (Worcestershire, 
UK) before and after 2 h of incubation at 37 
o
C.  
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2.6 Tables and Figures 
 
Figure 2.1.A: Cytotoxicity of small molecule drug genistein reported as normalized 
metabolic activity in HeLa and MDA-MB-231 cell lines in the presence of genistein at 
various concentrations. Metabolic activity was normalized to control with no drug 
presence (N=6, error bars represent standard deviation). 
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Figure 2.1.B: Cytotoxicity of small molecule drug methyl-β-cyclodextrin reported as 
normalized metabolic activity in HeLa and MDA-MB-231 cell lines in the presence of 
methyl-β-cyclodextrin at various concentrations. Metabolic activity was normalized to 
control with no drug presence (N=6, error bars represent standard deviation). 
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Figure 2.1.C: Cytotoxicity of small molecule drug chlorpromazine reported as 
normalized metabolic activity in HeLa and MDA-MB-231 cell lines in the presence of 
chlorpromazine at various concentrations. Metabolic activity was normalized to control 
with no drug presence (N=6, error bars represent standard deviation). 
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Figure 2.1.D: Cytotoxicity of small molecule drug amantadine reported as normalized 
metabolic activity in HeLa and MDA-MB-231 cell lines in the presence of amantadine at 
various concentrations. Metabolic activity was normalized to control with no drug 
presence (N=6, error bars represent standard deviation). 
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Figure 2.2: Cytotoxicity of unmodified 25 kDa PEI reported as normalized metabolic 
activity in HeLa and MDA-MB-231 cell lines in the presence of PEI at various 
concentrations. Metabolic activity was normalized to control with no PEI presence (N=6, 
error bars represent standard deviation). 
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Figure 2.3.A: In vitro transfection of HeLa with unmodified PEI in the presence of 
caveolin- (genistein 50 µg/mL, mβCD 2mg/mL) and clathrin- (chlorpromazine 5mg/mL, 
amantadine 1mM) inhibiting drugs at different polymer/DNA ratios. Gene delivery 
activity was normalized to control with no drug presence (N=4, error bars represent 
standard deviation; t-test: *,  p<0.05 compared to the same polyplex in the absence of 
drug). 
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Figure 2.3.B: In vitro transfection of MDA-MB-231 with unmodified PEI in the presence 
of caveolin- (genistein 50 µg/mL, mβCD 2mg/mL) and clathrin- (chlorpromazine 
5mg/mL, amantadine 1mM) inhibiting drugs at different polymer/DNA ratios. Gene 
delivery activity was normalized to control with no drug presence (N=4, error bars 
represent standard deviation; t-test: *,  p<0.05 compared to the same polyplex in the 
absence of drug). 
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Figure 2.4: The effective diameters of unmodified 25 kDa PEI polyplexes before and 
after two hours incubation at 37°C at different polymer/DNA ratios (N=5, error bars 
represent standard deviation; t-test: #,  p<0.05 compared the effective diameter of 
polyplex at 1:1 w/w ratio to 2:1 and 4:1 w/w ratios at 0 and 2 hours incubation). 
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Figure 2.5: The zeta potential of unmodified 25 kDa PEI polyplexes before and after two 
hours incubation at 37°C at different polymer/DNA ratios (N=5, error bars represent 
standard deviation; t-test: #,  p<0.05 compared the effective diameter of polyplex at 1:1 
w/w ratio to 2:1 and 4:1 w/w ratios at 0 and 2 hours incubation). 
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Figure 2.6.A: In vitro transfection of HeLa with various % Tf-PEI at 4:1 polymer/DNA 
w/w ratio (N=4, error bars represent standard deviation; t-test: *,  p<0.05 compared gene 
delivery activity of 25% Tf-PEI polyplexes to other polyplexes). 
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Figure 2.6.B: In vitro transfection of MDA-MB-231 with various % Tf-PEI at 4:1 
polymer/DNA w/w ratio (N=4, error bars represent standard deviation; t-test: *,  p<0.05 
compared gene delivery activity of 25% Tf-PEI polyplexes to other polyplexes). 
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Figure 2.7.A: In vitro transfection of HeLa with various molar ratio of Fol-PEI at 4:1 
polymer/DNA w/w ratio (N=4, error bars represent standard deviation; t-test: *,  p<0.05 
compared gene delivery activity of 0.8 Fol-PEI polyplexes to other polyplexes). 
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Figure 2.7.B: In vitro transfection of MDA-MB-231 with various molar ratio of Fol-PEI 
at 4:1 polymer/DNA w/w ratio (N=4, error bars represent standard deviation; t-test: *,  
p<0.05 compared gene delivery activity of 0.8 Fol-PEI polyplexes to other polyplexes). 
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Figure 2.8.A: In vitro transfection of HeLa with various concentration of free transferrin 
ligand with 25% Tf-PEI at 4:1 polymer/DNA w/w ratio. Gene delivery activity was 
normalized to control with no free transferrin presence (N=4, error bars represent 
standard deviation; t-test: * and **,  p<0.05). 
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Figure 2.8.B: In vitro transfection of MDA-MB-231 with various concentration of free 
transferrin ligand with 25% Tf-PEI at 4:1 polymer/DNA w/w ratio. Gene delivery 
activity was normalized to control with no free transferrin presence (N=4, error bars 
represent standard deviation; t-test: * and **,  p<0.05). 
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Figure 2.9.A: In vitro transfection of HeLa with various concentration of free folate 
ligand with 0.8 Fol-PEI at 4:1 polymer/DNA w/w ratio. Gene delivery activity was 
normalized to control with no free folate presence (N=4, error bars represent standard 
deviation; t-test: * and **,  p<0.05). 
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Figure 2.9.B: In vitro transfection of MDA-MB-231 with various concentration of free 
folate ligand with 0.8 Fol-PEI at 4:1 polymer/DNA w/w ratio. Gene delivery activity was 
normalized to control with no free folate presence (N=4, error bars represent standard 
deviation; t-test: **,  p<0.05). 
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Figure 2.10.A: In vitro transfection of HeLa with unmodified PEI, 10% & 25% Tf-PEI, 
and 0.8, 5, and 9 Fol-PEI in the presence of caveolin- (genistein 50 µg/mL, mβCD 2 
mg/mL) and clathrin- (chlorpromazine 5 mg/mL, amantadine 1 mM) inhibiting drugs at 
different polymer/DNA ratio. Gene delivery activity was normalized to control with no 
drug presence (N=4, error bars represent standard deviation; t-test: #,*,  p<0.05). 
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Figure 2.10.B: In vitro transfection of MDA-MB-231 with unmodified PEI, 10% & 25% 
Tf-PEI, and 0.8, 5, and 9 Fol-PEI in the presence of caveolin- (genistein 50 µg/mL, 
mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 mg/mL, amantadine 1 mM) inhibiting 
drugs at different polymer/DNA ratio. Gene delivery activity was normalized to control 
with no drug presence (N=4, error bars represent standard deviation; t-test: #,*,†,  
p<0.05). 
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Figure 2.11: The effective diameters of unmodified PEI, Tf-PEI, and Fol-PEI polyplexes 
before and after two hours incubation at 37°C at 4:1 w/w ratio (N=10, error bars 
represent standard deviation; t-test: #,  p<0.05; * represents data unavailable due to size 
of the sample being out of instrument measuring range). 
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Figure 2.12: The zeta potential of unmodified PEI, Tf-PEI, and Fol-PEI polyplexes 
before and after two hours incubation at 37°C at 4:1 w/w ratio (N=10, error bars 
represent standard deviation; t-test: #,  p<0.05). 
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Figure 2.13: Synthesis of Tf-PEI by conjugating thiolated PEI with Sulfo-KMUS linked 
transferrin protein [19]. 
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Figure 2.14: Synthesis of Fol-PEI by conjugating NHS activated folate with PEI [21].
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Chapter 3 
Effect of Clathrin- and Caveolin-Dependent Endocytosis on 
Biodegradable and Acetylated PEI-Mediated Gene Delivery 
 
3.1 Introduction 
In Chapter 2, we have demonstrated the effects of endocytosis pathways on PEI gene 
delivery using small molecule drugs. To further the study, we have investigated which 
endocytic pathway degradable and acetylated PEI derivatives utilize in gene delivery and 
explored if the difference between PEI and PEI derivatives plays a role in gene delivery 
when a particular uptake pathway is inhibited. 
 
Two novel PEI derivatives, biodegradable PEI and acetylated PEI, have been synthesized 
and were demonstrated to transfect more efficiently than unmodified PEI. Biodegradable 
PEI was first synthesized by crosslinking 800 Da PEI with 1,3-butanediol diacrylate and 
1,6-hexanediol diacrylate via a Michael-addition reaction. The resulting biodegradable 
PEIs demonstrated several fold increase in gene delivery activity and are less toxic 
compared to unmodified 25 kDa PEI [1-2]. To improve upon this study, 800 Da PEI was 
crosslinked with 1,6-hexanediol diacrylate and catalyzed by polymer supported 
PVP(Fe(III)) (Figure 3.1) [3]. The resulting reaction produced biodegradable PEIs 
(D.PEIs) with wider molecular weight range, and those D.PEIs show minimal toxicity 
and higher gene delivery activity than unmodified PEI. 
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Acetylated PEI was synthesized in the Pack lab through the acetylation of primary and 
secondary amines of 25 kDa PEI by reaction with acetic anhydride (Figure 3.2) [4]. The 
elimination of some amine groups present in PEI through acetylation led to the reduction 
of cationic charge of the polymer and enhanced the dissociation of DNA from the 
polyplexes in physiological condition. Forrest et al. and Gabrielson et al. have shown that 
various degrees of PEI acetylation result in 20-60 fold increase in gene delivery activity 
compared to unmodified 25 kDa PEI, depending on cell line [4-5]. 
 
In this chapter, we report the results of gene delivery studies performed with HeLa 
(human cervical adenocarcinoma cells) and MDA-MB-231 (human breast 
adenocarcinoma) using biodegradable PEI, acetylated PEI, and unmodified 25 kDa PEI 
in the presence of small molecule drugs inhibiting clathrin- and caveolin-dependent 
endocytosis. D.PEIs with molecular weight 48, 6.2, and 1.2 kDa (labeled D.PEI-48, 
D.PEI-6.2, and D.PEI-1.2, respectively) and 43% acetylated PEI (labeled AcPEI-43%) 
were synthesized and used in this study. Similar to Chapter 2, the decrease in gene 
delivery activity upon inhibiting a specific endocytic pathway indicates that the 
corresponding pathway is involved in efficient gene delivery, and vice versa. 
 
3.2  Results 
 
3.2.1 Synthesis and Characterization of Biodegradable PEI  
Three biodegradable PEI derivatives were synthesized by cross-linking equal moles of 
800 Da PEI with 1,6-hexanediol diacrylate, and catalyzed with 0.2, 0.15, and 0.1 molar 
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equivalent of PVP(Fe(III)) catalyst per mole of PEI (Figure 3.1). Using capillary 
viscometry, the molecular weights of the three D.PEI samples were determined as 48 
kDa, 6.2 kDa, and 1.2 kDa (Table 3.1) [10]. To investigate the structure and degradation 
of D.PEIs, 
1
H spectra of the samples were obtained before and after 37
o
C incubation in 
D2O. The 
1
H spectra show ester linkages connecting PEI and 1,6-hexanediol diacrylate 
prior to incubation (Figure 3.3). To determine the degree of degradation of D.PEIs, the 
relative number of methylene protons in the ester bond and in the hydroxyl group was 
measured by integrating the corresponding peaks in the spectra taken at 24, 72, and 192 h 
at 37 ºC (Figure 3.4) [11]. Both D.PEI-48 and D.PEI-1.2 had half of the initial ester bond 
remaining intact after 24 h of incubation, while D.PEI-6.2 reached its half-life after 72 h 
incubation. 
 
Highly cross-linked, low molecular weight PEI is expected to behave like its high 
molecular weight non-cross-linked counterpart due to similar molecular weights. 
Approximate cross-linking density of each D.PEIs was measured by elemental analysis 
through mass balances (Table 3.2). D.PEI-48, D.PEI-6.2, and D.PEI-1.2 have cross-
linking density, defined as mole percent of nitrogen atoms in PEI attached to 1,6-
hexanediol diacrylate, of 16.9%, 15.1%, and 14.1%, respectively. To determine whether 
the D.PEIs are linear or branched, the number of PEI chains cross-linked with 1,6-
hexanediol diacrylate was calculated (Table 3.2) [12-13]. The results show a direct 
relationship between cross-linking density and the number of diacrylate linked to a PEI 
chain. Each D.PEI sample has more than two diacrylates attached with a single PEI 
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chain, which indicates that D.PEIs had branched structure. Specifically, the D.PEI-48 has 
a high level of branching by having more than three diacrylates linked to a PEI chain. 
 
A wide range of PEI/DNA weight-to-weight ratios (w/w ratios) for each D.PEI were 
tested to study their gene delivery effectiveness compared to unmodified PEI (Figure 
3.5.A-3.5B). The D.PEIs show higher gene delivery activity than unmodified PEI in both 
HeLa and MDA-MB-231 cells. D.PEI-48, at 4:1 w/w ratio, outperformed the other three 
polymers at their optimal w/w ratio and, specifically, was two- to three- fold better than 
unmodified PEI. As expected, as the amount of polymer used in making the polyplexes 
increased, after it reached a critical w/w ratio, the gene delivery activity decreased 
drastically.  
 
3.2.2 Transfection with Biodegradable PEI in the Presence of Pathway-Inhibiting 
Drugs 
Four small molecule drugs were used to specifically inhibit either clathrin- or caveolin-
dependent endocytosis for subsequent D.PEI gene delivery study. Genistein and mβCD 
inhibit caveolin-dependent endocytosis, and chlorpromazine and amantadine inhibit 
clathrin-dependent endocytosis [6-9] (Figure 3.6.A-3.6.F). For HeLa, in the presence of 
caveolin-inhibiting drugs, all three D.PEIs show less than 50% gene delivery activity 
compared to no drug control in tested w/w ratios, with the exception of D.PEI-1.2 at high 
w/w ratios. In the presence of clathrin-inhibiting drugs, gene delivery activity of D.PEIs 
was enhanced by one- to three-fold for w/w ratios four, eight, and ten. For MDA-MB-
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231, similar trends were observed. However, the enhancement of clathrin-dependent 
endocytosis was only observed at high w/w ratios, namely eight, ten, and fifteen.    
 
3.2.3 Biodegradable PEI Toxicity 
MTT metabolic assay was used to measure the cytotoxicity of D.PEIs used in this study 
to ensure the tested w/w ratios were not severely cytotoxic to the cells (Figure 3.7.A-
3.7.B). For HeLa, D.PEI-1.2 did not show significant cytotoxicity, while the other two 
D.PEIs induced approximately 55% cell viability at 50 µg/mL. However, in the 
concentration ranges tested in gene delivery study, ~2-15 µg/mL, all four tested PEI 
derivatives show over 80% cell viability. As a comparison, unmodified PEI reduced 
HeLa viability to minimal at only 10 µg/mL concentration. Compared to HeLa, MDA-
MB-231 seems to be less sensitive to D.PEI cytotoxicity. In tested concentrations, MDA-
MB-231 did not drop below 80% viability for D.PEIs and reached 10% viability at 30 
µg/mL of unmodified PEI. 
 
3.2.4 Biodegradable PEI Polyplex Sizing and Zeta Potential  
The effective diameter of D.PEI polyplexes before and after two hours incubation at 37°C 
was characterized using dynamic light scattering (Figure 3.8). The effective diameter of 
the polyplexes seems to be directly related to the molecular weight of the D.PEIs. At 2:1 
and 4:1 w/w ratios prior to incubation, D.PEI-48 polyplexes were ~300-400 nm, while 
D.PEI-6.2 and D.PEI 1.2 polyplexes were ~200-250 nm and ~150 nm, respectively. 
However, at higher w/w ratios, the difference in effective diameters diminished and the 
size of all the polyplexes were in the range of 100-150 nm. After 37°C incubation, the 
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effective diameter of D.PEI polyplexes increased by half at lower w/w ratios, except for 
D.PEI-1.2 polyplexes where they maintained similar size. At 2:1 and 4:1 w/w 
D.PEI/DNA, D.PEI-48, D.PEI-6.2, and D.PEI-1.2 polyplexes’ effective diameter were 
~500 nm, ~300 nm, and ~170 nm, respectively. At high w/w ratios, D.PEI-48 polyplexes’ 
effective diameter ranging from 150-300 nm, while D.PEI-6.2 and D.PEI-1.2 polyplexes 
were about 150 nm in diameter. In addition to dynamic light scattering, zeta potential of 
all the polyplexes were also characterized using zetasizer (Figure 3.9). All polyplexes 
show zeta potential between 20-30 mV before and after incubation, with only two 
exceptions where they show ~15 mV. 
 
3.2.5 Transfection with Acetylated PEI in the Presence of Pathway Inhibiting  
Drugs 
Forty-three percent acetylated PEI was tested, along with unmodified PEI, at various w/w 
ratios to study its gene delivery performance (Figure 3.10.A-3.10.B). AcPEI-43% shows 
higher gene delivery activity than unmodified PEI across tested w/w ratios for both HeLa 
and MDA-MB-231 cells, except at 2:1 where minimum gene delivery activity was 
observed. AcPEI-43% performed three- to four-fold better than unmodified PEI at their 
respective optimal transfection w/w ratios, namely 6:1 and 2:1. 
 
To investigate the effect of clathrin- and caveolin-dependent endocytosis on AcPEI-43% 
gene delivery, four small molecule drugs were used to inhibit the two pathways (Figure 
3.11.A-3.11.B). In HeLa, the effects of uptake pathway inhibition were observed only at 
higher w/w ratios (4:1, 6:1, and 8:1). The abnormal trend observed for 2:1 w/w ratio was 
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most likely due to the minimal gene delivery activity shown by AcPEI-43% with or 
without drugs, as discussed above. In the presence of caveolin-inhibiting drugs, the gene 
delivery of AcPEI-43% was reduced by 50-90% compared to no drug control. When 
clathrin-dependent endocytosis was inhibited, the gene delivery activity of AcPEI-43% 
was enhanced by 20-60%. For MDA-MB-231, the overall trends were similar to HeLa. 
Gene delivery activity of AcPEI-43% was decreased by 40-90% and was increased by 
20-40% in the presence of caveolin- and clathrin-inhibiting drugs, respectively. 
 
3.2.6 Acetylated PEI Toxicity 
The cytotoxicity of AcPEI-43% in HeLa and MDA-MB-231 was quantified using MTT 
assay (Figure 3.7.A-3.7.B). AcPEI-43% induced 50% viability in both cell lines at 
approximately 45 µg/mL, which indicates the polymer was relatively nontoxic in the 
tested concentration range. In addition, even though only ~43% of the primary and 
secondary amine groups of the 25 kDa PEI were acetylated, the cytotoxicity of the 
polymer was significantly reduced relative to unmodified 25 kDa PEI. Compared to 
D.PEIs, AcPEI-43% shows similar cytotoxicity to the two higher molecular weight 
D.PEIs in HeLa and is significantly more toxic than all three D.PEIs in MDA-MB-231. 
 
3.2.7 Acetylated PEI Polyplex Sizing and Zeta Potential  
The effective diameters of AcPEI-43% polyplexes were approximately 180 nm for 2:1, 
4:1 and 6:1 w/w ratio polyplexes and 80 nm for 8:1 w/w polyplexes before 37°C 
incubation (Figure 3.12). After two hours incubation, the effective diameters of the 
AcPEI-43% polyplexes increased slightly from ~180 nm to ~210 nm and from ~80 nm to 
87 
 
~90 nm, though these changes were not statistically significant. For AcPEI-43%, 2:1, 4:1 
and 6:1 w/w ratio polyplexes’ zeta potential were in the range of 20-30mV before and 
after incubation (Figure 3.13). The zeta potential of AcPEI-43% polyplexes at 8:1 w/w 
ratio was 12 mV before incubation and 19 mV after incubation. 
 
3.3 Discussion 
In Chapter 2, we studied the effect of clathrin- and caveolin-dependent endocytoses on 
PEI gene delivery and concluded that caveolin-dependent endocytosis is important to 
successful PEI gene delivery for both HeLa and MDA-MB-231. In this chapter, we 
further explored the effect of endocytosis on novel PEI derivatives that were synthesized 
in the Pack lab [2-5]. The first PEI derivative was D.PEI, which was synthesized by 
crosslinking 800 Da PEI with diacrylate through biodegradable ester linkage, resulting in 
D.PEI with various molecular weight. The second PEI derivative was AcPEI-43%, which 
was synthesized by acetylating primary and secondary amine groups of 25 kDa PEI. This 
investigation was designed to elucidate whether cancer cells would use a different uptake 
pathway to internalize modified PEI polymer/DNA complexes, versus unmodified PEI 
polymer/DNA complexes, for in vitro gene delivery. For both PEI derivatives, one would 
expect they utilize the same uptake mechanism as their unmodified counterpart due to the 
similarity of their monomer’s chemical structure. Specifically, as a result of D.PEIs’ 
higher overall gene delivery efficacy and lower cytotoxicity, the enhancement of gene 
delivery activity for D.PEI polyplexes when clathrin-dependent endocytosis was inhibited 
should be higher than unmodified PEI. For AcPEI-43%, since some of the cationic amine 
groups were “capped” and reduced its ability to escape from endosome, one would expect 
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the improvement of AcPEI-43% gene delivery activity, when clathrin-dependent 
endocytosis is inhibited, would be less drastic compared to D.PEIs. 
 
The four small molecule drugs that were chosen to specifically inhibit the two pathways 
and their respective concentrations used in this study were the same as in Chapter 2. 
D.PEIs with molecular weight 48, 6.2, and 1.2 kDa were used in gene delivery studies in 
the presence of those four drugs (Figure 3.6.A-3.6.F). Regardless of cell type and 
molecular weight of D.PEI, the effects of the drugs were observed only at higher w/w 
ratios, particularly for clathrin-dependent endocytosis inhibition. This is in good 
agreement with what we observed in the previous chapter, where a critical amount of 
polymer is needed in order for a notable effect of uptake pathway on gene delivery to be 
observed. For HeLa, in the presence of caveolin-inhibiting drugs (genistein and mβCD), 
the gene delivery activity of D.PEIs were reduced at least by half. On the contrary, in the 
presence of clathrin-inhibiting drugs (chlorpromazine and amantadine), the gene delivery 
activity of D.PEIs were enhanced by 50-300% compared to no drug control. For MDA-
MB-231, similar trends were observed when caveolin-dependent endocytosis was 
inhibited, where gene delivery activity was decreased significantly by genistein and 
mβCD regardless of tested w/w ratios or D.PEI’s molecular weight. When clathrin-
dependent endocytosis was disrupted, for D.PEI-48 and D.PEI-6.2, the gene delivery 
activity enhancement (two- to six-fold) was observed only at 10:1 and 15:1 w/w ratios. 
For D.PEI-1.2, the improvement of gene delivery activity was minor (20-40%) compared 
to the other two D.PEIs in the presence of chlorpromazine. In the presence of 
amantadine, the gene delivery activity of D.PEI-1.2 decreased by 25%. The trend shown 
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by D.PEI-1.2 when clathrin-dependent endocytosis was inhibited could be contributed by 
D.PEI-1.2 lower overall gene delivery effectiveness compared to the other D.PEIs. 
 
In the tested range of w/w ratios, both HeLa and MDA-MB-231 show over 90% viability 
for all D.PEIs, which indicates that cytotoxicity did not contribute to the change of gene 
delivery activity observed in the presence of pathway inhibiting drugs (Figure 3.7.A-
3.7.B). Most D.PEI polyplexes display effective diameter in the range of 150-300 nm, 
except for D.PEI-48 at 2:1 and 4:1 w/w ratios (Figure 3.8). Those two polyplexes’ 
effective diameters were ~320 nm and ~500 nm before and after incubation. This is 
probably due to the large polymer structure and not enough negatively charged DNA to 
condense the polyplexes. Since clathrin-dependent endocytosis has a maximum particle 
size limit of 200 nm, the DLS results for D.PEIs indicated it is likely that some of the 
D.PEI polyplexes used in this study utilized caveolin-dependent endocytosis (200-500 
nm) over clathrin-dependent endocytosis, which might partially explain why D.PEIs 
performed better than their unmodified counterpart [14]. Unlike DLS measurement, zeta 
potentials of D.PEI polyplexes were more uniform (Figure 3.9). The zeta potentials of all 
polyplexes were in the range of 20-30 mV both before and after the incubation. These 
results indicate that D.PEI polyplexes were positively charged stable nano-scale 
complexes. 
 
For AcPEI-43%, an analogous study was performed (Figure 3.11.A-3.11.B). The 
unexpected trend observed at 2:1 w/w ratio could be explained by the fact that AcPEI-
43% transfected poorly in HeLa and MDA-MB-231 at this ratio (Figure 3.10.A-3.10.B), 
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resulting in inaccurate results. For higher PEI/DNA ratio, in the presence of genistein and 
mβCD, the gene delivery activity of AcPEI-43% was decreased by 40-90%, compared to 
no drug control. When clathrin-dependent endocytosis was inhibited, the improvement of 
AcPEI-43% gene delivery activity was only 10-60% increased, which is not as significant 
as the drug effects on unmodified PEI and D.PEIs. This might be partially due to the 
elimination of some amine groups through acetylation, which led to the reduction of the 
endosomal escape capability of the polyplexes. Another factor that might contribute to 
the lesser improvement could be the higher cytotoxicity of AcPEI-43% polyplexes 
(Figure 3.7.A-3.7.B). In the w/w ratios used in this study for AcPEI-43%, HeLa shows 
approximately 90% viability and MDA-MB-231 shows 80% viability. The combination 
of the cytotoxicity of the small molecule drug and AcPEI-43% polyplexes themselves 
might negatively affect the enhancement of gene delivery when clathrin-dependent 
endocytosis was inhibited. For most AcPEI-43% polyplexes at tested w/w ratios, 
effective diameter was in the range of 160-230 nm, with the exception of 8:1 w/w ratio, 
where they were ~80 nm. Similarly, zeta potential of AcPEI-43% polyplexes was in the 
range of 20-30 mV, except for 8:1 w/w ratio polyplexes. Both the size and zeta potential 
differences between AcPEI-43% polyplexes at various w/w ratios did not seem to 
influence the effects of pathway inhibiting drugs on gene delivery activity. 
 
In conclusion, the results presented in this chapter indicate overall that D.PEI and AcPEI-
43% polyplexes used caveolin-dependent endocytosis for successful gene delivery to 
both HeLa and MDA-MB-231, regardless of differences in chemistry/structure, size, and 
zeta potential compared to unmodified PEI. 
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3.4 Materials and Methods 
 
3.4.1 Cells and Plasmids 
The MDA-MB-231 human breast carcinoma cell line was purchased from the American 
Type Culture Collection (Manassas, VA). The HeLa human cervical carcinoma cell line 
was a gift from Dr. Sandra McMasters (University of Illinois, Urbana, IL). Cells were 
cultured according to their ATCC protocols at 37 
o
C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM). The growth medium was supplemented with 10% fetal bovine 
serum (FBS) and 10% penicillin-streptomycin. The 5.3-kilobase expression vector pGL3 
(Promega, Madison, WI), coding for firefly luciferase gene driven by the SV40 promoter 
and enhancer, was purchased from Elim Biopharm (Hayward, CA) and used without 
further purification. 
 
3.4.2 Additional Chemicals 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless specified 
otherwise. Sulfo-KMUS, 2-iminothiolane, and BCA Protein Assays were purchased from 
Thermo Fisher Scientific (Rockford, IL). PD-10 desalting columns were obtained from 
GE Healthcare (Pittsburgh, PA). Amicon 100,000 MWCO centrifugal filters were 
purchased from Millipore (Billerica, MA). 
 
3.4.3 Biodegradable and Acetylated PEI Syntheses 
Degradable PEI of various molecular weights was synthesized according to the reaction 
in Shum et al. [3]. Briefly, degradable PEI was synthesized by cross-linking 800 Da 
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branched PEI with 1,6-hexanediol diacrylate cross-linker. One g of 800 Da branched PEI 
was dissolved in 10 mL of methanol at room temperature in a scintillation vial. Various 
molar equivalents of PVP(Fe(III)) catalyst to mole of PEI, between 0.05 to 0.15, in 
addition to an equimolar amount of cross-linker to PEI, were added into the mixture to 
form a suspension. The mixture was sealed with a screw cap, wrapped in Parafilm, and 
stirred with a stir bar overnight at 60
o
C. After 24 h, the mixture was transferred into a 15 
mL polystyrene tube and centrifuged at 4500 rpm for 10 min to remove the catalyst. 
Unreacted materials were extracted using approximately 15 mL of petroleum ether. The 
methanol phase was collected, and methanol was removed by using a rotating evaporator 
at 67 
o
C and 150 rpm for approximately 25 min until only viscous degradable PEI sample 
was left. Polymer was used without further purification and stored at -80
o
C. 
 
To determine the molecular weight of degradable PEI, capillary viscometery was used as 
described previously by von Harpe et al. [10]. Briefly, polymers were dissolved in 0.5 M 
NaNO3 to achieve three different solutions with concentrations between 1 and 5 g/L, and 
the viscosities were measured using a kinematic viscometer (Cannon, State College, PA) 
at 25 
o
C. Due to the high cationic charge of the polymer, the high salt concentration of 
NaNO3 is needed in order to obtain a linear relationship between polymer concentration 
and viscosity. Reduced, specific, inherent, and limiting viscosities of the polymer 
solution were calculated using Equations 1, 2, and 3: 
000 //)( ttsp ≈−= ηηηη …………………………………(1) 
cspred /ηη = ………………………………………………(2) 
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where η  is the viscosity of the polymer sample in solvent, 0η  is the viscosity of the 
solvent (determined experimentally), 
spη  is the specific viscosity of the polymer sample 
in solvent, t  is the time the polymer sample in solvent took to go through the viscometer, 
0t  is the time the solvent took to go through the viscometer, redη  is the reduced viscosity 
of the polymer sample in solvent, c  is the concentration of polymer in the solvent, and 
][η is the intrinsic viscosity of the polymer sample in solvent. 
 
Plotting ])log([η against )log(MW , a linear relationship was constructed using 
Staudinger-Mark-Houwink relationship with known molecular weight PEI standards 
(Eqn 4):  
2)log()26.0(])log([ −= MWη ……………………….......(4) 
By measuring the viscosity of each cross-linked polymer sample, one can calculate the 
molecular weight of the sample by using Eqn 1-4. 
 
Acetylated PEI was synthesized according to the reaction in Gabrielson et al. [5]. Briefly, 
0.5 g branched 25-kDa PEI was dissolved in a 20 mL scintillation vial with 3mL of 
methanol. Different molar ratios of acetic anhydride were added to the PEI solution to 
achieve the desired degree of acetylation, and the vial was then sealed. The reaction was 
carried out at 65 °C with constant stirring for 4 h. After 4 h, the reaction was quenched 
with 0.5 mL double distilled water and the solvent was removed under reduced pressure. 
The remaining solution was purified by PD-10 desalting column. The purified polymer 
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was then concentrated by lyophilization, stored at -80 °C, and was used without further 
purification. 
 
To determine the extent of acetylation, each polymer was dissolved in D2O (Sigma-
Aldrich), and 
1
H NMR spectra were acquired on a Varian Unity 400 with a 5-mm probe.  
The extent of primary and secondary amine acetylation was determined by peak 
integration using the following formula: 
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where M′ is the integration of δ 1.7−1.75 peaks (R-NHCOCH3, acetylated primary 
amines), M′′ is the integration of δ 1.8−1.85 peaks (R2-NCOCH3, acetylated primary 
amines), and Ebb is the integration of δ 2.3−2.8 peaks 
([CH2CH2N]x[CH2CH2NH]y[CH2CH2NH2]z, ethylene backbone). N′ and N′′ are mole 
fractions of primary and secondary amines of the PEI starting material, respectively. All 
integration was performed using the WinNuts software (Acorn NMR, Livermore, CA). 
 
3.4.4 In Vitro Transfection 
Cells (MDA-MB-231 or HeLa) were cultured in DMEM with 10% fetal bovine serum 
and 10% penicillin-streptomycin. In a 24-well plate, 8x10
4
 cells/well were seeded in 
growth medium with serum 24 h before transfection. On the day of transfection, growth 
medium was replaced with fresh serum-free DMEM. For transfections performed in the 
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presence of caveolae inhibitors (50 µg/mL genistein, 2 mg/mL methyl-β-cyclodextrin) or 
clathrin inhibitors (5 µg/mL chlorpromazine, 1 mM amantadine), the growth medium was 
replaced with folate-free, serum-free DMEM containing the desired drug one hour prior 
to transfection. Before transfection, 50 µL of polyplexes in a solution of 120 mM NaCl 
and 16 mM PIPES at pH 7.2 were formed with 0.5 µg pGL3 and various amount of 
polymer to achieve desired weight-to-weight ratio. The polyplexes were incubated at 
room temperature for 15 min and then added into each well (50 µL polyplexes/well). 
Two hours post-transfection, DMEM was replaced with fresh growth medium with serum 
and incubated overnight. Twenty-four hours post-transfection, luciferase expression was 
determined using the Promega Luciferase Assay System (Promega, Madison, WI), which 
reports expression levels as relative light units (RLU) as measured on the Lumat L 9507 
luminometer (Berthold, GmbH, Germany). Each experiment was performed in 
quadruplicate. Luciferase expression results (RLUs) were normalized to total cell protein 
amount using BCA Protein Assay. 
 
3.4.5 Cytotoxicity Measurement 
The cytotoxicity of polymers on the MDA-MB-231 and HeLa cells was characterized 
using the CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT) (Promega) 
according to the manufacturer’s protocol. Briefly, 8x10
3
 cells/well were seeded in a 96-
well microplate in growth medium containing 10% FBS and incubated at 37
o
C and 5% 
CO2 overnight. Approximately 24 h after seeding, the medium was replaced with folate 
free, serum-free DMEM, and various amounts of drug or polymer was added to the cells 
to achieve target concentrations. Following a 3 h incubation period at 37
o
C and 5% CO2, 
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the medium was replaced with fresh serum-containing medium and incubated for another 
24 h, after which 15 µL of the Dye Solution was added into each well, and cells were 
incubated for another 4 h. After incubation, 100 µL of the Solubilization Solution/Stop 
Mix was added into each well and incubated for another 1 h. Afterward, the absorbance 
at 570 nm, with a reference wavelength of 650 nm, was measured using an absorbance 
plate reader. The absorbance of medium only was subtracted from the viable cell 
absorbance and normalized to the absorbance reading of cells with no drug/polymer 
present. Each drug/polymer and drug/polymer concentration were tested five times in 
each experiment.  
 
3.4.6 Dynamic Light Scattering and Zeta Potential 
One microgram of DNA was diluted into 200 µL of a solution of 120 mM NaCl and 16 
mM PIPES at pH 7.2. Polymer was dissolved in double distilled water. The amount of 
polymer sample used was determined by the transfection ratio and diluted into 200 µL of 
120 mM NaCl, 16 mM PIPES at pH 7.2, and was added to the 200 µL DNA/PIPES 
solution to form the desired polymer and DNA weight–to-weight ratio polyplexes. The 
polyplexes were incubated at room temperature for 15 min, and double distilled water 
was added to reach a final sample volume of 1 mL. The polyplexes’ size and zeta 
potential were measured by Malvern Instruments’ Zetasizer Nano ZS (Worcestershire, 
UK) before and after 2 h of incubation at 37 
o
C.  
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3.6 Tables and Figures 
 
Figure 3.1: Synthesis of biodegradable PEI derivatives. 800 Da PEI is cross-linked with 
1,6-hexanediol diacrylate in methanol overnight at 60
o
C, catalyzed by PVP(Fe(III)) 
heterogenous catalyst. The diacrylate groups can react with primary and secondary 
amines of the PEI. [3] 
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Figure 3.2: Synthesis of acetylated PEI derivatives. Primary and sceondary amines from 
25 kDa PEI reacted with acetic anhydride to generate secondary amides and tertiary 
amides in methanol for four and a half hour at 65
o
C. [4,5] 
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Table 3.1: Polymer concentrations, viscosity measurements, reduced viscosities, and 
molecular weights of biodegradable PEIs 
Molar 
Ratio of 
Catalyst to 
PEI 
Concentration 
(mg/mL) 
Average 
Time (s) 
SD Reduced 
Viscosity 
(dL/g) 
Molecular 
Weight 
(kDa) 
 2 240.79 0.33   
0.2  4 247.44 0.44 0.0968 6.2 
 6 250.00 0.49   
 2 232.83 13.59   
0.15  4 243.71 0.17 0.0636 1.2 
 7 250.75 0.34   
 2 243.58 0.45   
0.1  4 246.63 0.21 0.1651 48 
 7 251.59 0.12   
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Figure 3.3: NMR spectra of unmodified PEIs and D.PEIs. 1) Unmodified 800 Da PEI, 2) 
unmodified 25 kDa PEI, 3) 48 kDa D.PEI, 4) 6.2 kDa D.PEI, and 5) 1.2 kDa D.PEI. 
D.PEI spectrum peak labels: (a) δ=4.1 ppm, -COOCH2, ester linker; (b) δ=3.5-3.6 ppm, -
HOCH2, hydrolyzed ester linker; (c) δ=3.34ppm, methanol residual; (d) δ=2.47-3.3 ppm, 
CH2CH2N, PEI ethylenes; (e) δ =2.33-2.47 ppm, CH2CH2NHCH2CH2COOCH2, ester 
linker; (f) δ=1.40-1.60 ppm, -COOCH2CH2, ester linker; and (g) δ =1.25-1.40 ppm, -
COOCH2CH2CH2, ester linker.  
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Figure 3.4: Degradation of D.PEIs in D2O at 37
o
C for various incbuation periods. 
Samples were measured with 400 MHz 
1
H NMR. Degradation was calculated based on 
the integrals of the ester linker and hydrolyzed ester linker peaks. 
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Table 3.2: Elemental analysis results, calculated % cross-linking and # diacrylate cross-
linked with a PEI chain for each D.PEI sample 
D.PEI 
Samples 
Weight % 
Carbon 
Weight % 
Nitrogen 
Weight  % 
Hydrogen 
% Cross-
linking 
# Cross-
linker 
attached to a 
PEI chain 
48 kDa  46.85 19.96 10.46 16.9 3.14 
6.2 kDa  49.07 20.26 10.19 15.1 2.81 
1.2 kDa 50.65 20.46 10.50 14.1 2.62 
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Figure 3.5.A: In vitro transfection of HeLa with D.PEIs and unmodified 25 kDa PEI at 
different polymer/DNA ratio. Gene delivery activity was normalized to control with no 
drug presence (N=4, error bars represent standard deviation; t-test: *, p<0.05 compared 
gene delivery activity for D.PEIs and unmodified PEI at their respective optimal w/w 
ratio) 
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Figure 3.5.B: In vitro transfection of MDA-MB-231 with D.PEIs and unmodified 25 
kDa PEI at different polymer/DNA ratio. Gene delivery activity was normalized to 
control with no drug presence (N=4, error bars represent standard deviation; t-test: *, 
p<0.05 compared gene delivery activity for D.PEIs and unmodified PEI at their 
respective optimal w/w ratio) 
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Figure 3.6.A: In vitro transfection of HeLa with D.PEI-48 in the presence of caveolin- 
(genistein 50 µg/mL, mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 mg/mL, 
amantadine 1 mM) inhibiting drugs at different polymer/DNA ratio. Gene delivery 
activity was normalized to control with no drug presence (N=4, error bars represent 
standard deviation; t-test: *, p<0.05 compared to the same polyplex in the presence and 
absence of genistein and mβCD;  #,  p<0.05 compared to the same polyplex in the 
presence of chlorpromazine and amantadine and no drug control). 
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Figure 3.6.B: In vitro transfection of HeLa with D.PEI-6.2 in the presence of caveolin- 
(genistein 50 µg/mL, mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 mg/mL, 
amantadine 1 mM) inhibiting drugs at different polymer/DNA ratio. Gene delivery 
activity was normalized to control with no drug presence (N=4, error bars represent 
standard deviation; t-test: *, p<0.05 compared to the same polyplex in the presence and 
absence of genistein and mβCD;  #,  p<0.05 compared to the same polyplex in the 
presence of chlorpromazine and amantadine and no drug control). 
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Figure 3.6.C: In vitro transfection of HeLa with D.PEI-1.2 in the presence of caveolin- 
(genistein 50 µg/mL, mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 mg/mL, 
amantadine 1 mM) inhibiting drugs at different polymer/DNA ratio. Gene delivery 
activity was normalized to control with no drug presence (N=4, error bars represent 
standard deviation; t-test: *, p<0.05 compared to the same polyplex in the presence and 
absence of genistein and mβCD;  #,  p<0.05 compared to the same polyplex in the 
presence of chlorpromazine and amantadine and no drug control). 
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Figure 3.6.D: In vitro transfection of MDA-MB-231 with D.PEI-48 in the presence of 
caveolin- (genistein 50 µg/mL, mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 
mg/mL, amantadine 1 mM) inhibiting drugs at different polymer/DNA ratio. Gene 
delivery activity was normalized to control with no drug presence (N=4, error bars 
represent standard deviation; t-test: *, p<0.05 compared to the same polyplex in the 
presence and absence of genistein and mβCD;  #,  p<0.05 compared to the same polyplex 
in the presence of chlorpromazine and amantadine and no drug control). 
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Figure 3.6.E: In vitro transfection of MDA-MB-231 with D.PEI-6.2 in the presence of 
caveolin- (genistein 50 µg/mL, mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 
mg/mL, amantadine 1 mM) inhibiting drugs at different polymer/DNA ratio. Gene 
delivery activity was normalized to control with no drug presence (N=4, error bars 
represent standard deviation; t-test: *, p<0.05 compared to the same polyplex in the 
presence and absence of genistein and mβCD;  #,  p<0.05 compared to the same polyplex 
in the presence of chlorpromazine and amantadine and no drug control). 
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Figure 3.6.F: In vitro transfection of MDA-MB-231 with D.PEI-1.2 in the presence of 
caveolin- (genistein 50 µg/mL, mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 
mg/mL, amantadine 1 mM) inhibiting drugs at different polymer/DNA ratio. Gene 
delivery activity was normalized to control with no drug presence (N=4, error bars 
represent standard deviation; t-test: *, p<0.05 compared to the same polyplex in the 
presence and absence of genistein and mβCD;  #,  p<0.05 compared to the same polyplex 
in the presence of chlorpromazine and amantadine and no drug control). 
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Figure 3.7.A: Cytotoxicity of D.PEIs, AcPEI-43%, and unmodified 25 kDa PEI reported 
as normalized metabolic activity in HeLa cell line in the presence of PEI at various 
concentrations. Metabolic activity was normalized to control with no PEI presence (N=6, 
error bars represent standard deviation). 
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Figure 3.7.B: Cytotoxicity of D.PEIs, AcPEI-43%, and unmodified 25 kDa PEI reported 
as normalized metabolic activity in MDA-MB-231 cell line in the presence of PEI at 
various concentrations. Metabolic activity was normalized to control with no PEI 
presence (N=6, error bars represent standard deviation). 
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Figure 3.8: The effective diameters of D.PEI polyplexes before and after two hours 
incubation at 37°C at different polymer/DNA ratios (N=5, error bars represent standard 
deviation). 
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Figure 3.9: The zeta potential of D.PEI polyplexes before and after two hours incubation 
at 37°C at different polymer/DNA ratios (N=5, error bars represent standard deviation). 
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Figure 3.10.A: In vitro transfection of HeLa with AcPEI-43% and unmodified 25 kDa 
PEI at different polymer/DNA ratio. Gene delivery activity was normalized to control 
with no drug presence (N=4, error bars represent standard deviation; t-test: *, p<0.05 
compared gene delivery activity for AcPEI-43% and unmodified PEI at their respective 
optimal w/w ratio) 
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Figure 3.10.B: In vitro transfection of MDA-MB-231 with AcPEI-43% and unmodified 
25 kDa PEI at different polymer/DNA ratio. Gene delivery activity was normalized to 
control with no drug presence (N=4, error bars represent standard deviation; t-test: *, 
p<0.05 compared gene delivery activity for AcPEI-43% and unmodified PEI at their 
respective optimal w/w ratio) 
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Figure 3.11.A: In vitro transfection of HeLa with AcPEI-43% in the presence of 
caveolin- (genistein 50 µg/mL, mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 
mg/mL, amantadine 1 mM) inhibiting drugs at different polymer/DNA ratio. Gene 
delivery activity was normalized to control with no drug presence (N=4, error bars 
represent standard deviation; t-test: *, p<0.05 compared to the same polyplex in the 
presence and absence of genistein and mβCD;  #,  p<0.05 compared to the same polyplex 
in the presence of chlorpromazine and amantadine and no drug control). 
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Figure 3.11.B: In vitro transfection of MDA-MB-231 with AcPEI-43% in the presence 
of caveolin- (genistein 50 µg/mL, mβCD 2 mg/mL) and clathrin- (chlorpromazine 5 
mg/mL, amantadine 1 mM) inhibiting drugs at different polymer/DNA ratio. Gene 
delivery activity was normalized to control with no drug presence (N=4, error bars 
represent standard deviation; t-test: *, p<0.05 compared to the same polyplex in the 
presence and absence of genistein and mβCD;  #,  p<0.05 compared to the same polyplex 
in the presence of chlorpromazine and amantadine, and no drug control). 
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Figure 3.12: The effective diameters of D.PEI polyplexes before and after two hours 
incubation at 37°C at different polymer/DNA ratios (N=5, error bars represent standard 
deviation). 
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Figure 3.13: The zeta potential of D.PEI polyplexes before and after two hours 
incubation at 37°C at different polymer/DNA ratios (N=5, error bars represent standard 
deviation). 
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Chapter 4 
Generation of Modified Cancer Cells Expressing Tet-Inducible shRNA 
System to Inhibit Clathrin, Caveolin, and Lamin A/C Protein 
Expression and Their Effects on PEI-Mediated Gene Delivery In Vitro 
 
4.1 Introduction 
A primary goal of this thesis is to explore the effects of clathrin- and caveolin-dependent 
endocytic pathways on PEI-mediated gene delivery through experimentation in an animal 
model. Animal testing is a crucial “next step” towards clinical realization for a number of 
reasons: 1) in vitro experiments generally involve two-dimensional monolayer cell 
culture, whereas clinical therapy is applied to three-dimensional target sites in animals or 
patients; 2) circulation is a consideration in any clinical research, yet it is non-existent in 
vitro; 3) the presence of serum proteins in the bloodstream, which is lacking in in vitro 
experiment, is an important design parameter to take into account for any potential 
therapeutic treatment; and 4) the difference at the cell level, where cells may behave 
differently in culture and in an animal. All of these factors could negatively impact the 
efficacy of gene delivery. Therefore, it is critical for researchers to study both in vitro and 
in vivo performance when designing gene delivery systems [1-3].  In this project, a 
xenograft murine tumor model has been chosen to study the effect of endocytic pathway 
on in vivo gene delivery. Unlike in vitro experiments, it is impractical to inhibit or target 
endocytosis at the tumor site by dosing mice with small molecule drugs. To circumvent 
this problem, we have modified existing HeLa and MDA-MB-231 cell lines to express 
tetracycline-on (Tet-On) small hairpin RNA (shRNA) that targets the expression of 
clathrin (CLTC), caveolin (CAV), and Lamin A/C (LAM, as negative control). Various 
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studies have used such tetracycline (Tet) inducible shRNA expression to silence targeted 
genes in mammalian cells in vitro [4-6]. 
 
Small-hairpin RNA is a part of RNA interference (RNAi) technology, used to 
knockdown target protein expression. RNAi is a powerful process to down-regulate 
specific genes, resulting in the silencing of target protein expression [7-8]. The most 
commonly used gene silencing method is the application of small interfering RNA 
(siRNA), a double-stranded RNA (dsRNA) consisting of 19-21 nucleotides 
complementary to the targeted gene with two nucleotides overhanging at 3’ ends, in 
mammalian cells. When siRNA is delivered into the cytosol of target cells, the siRNA 
will pair with and cleave the target mRNA, stopping the target gene from translation and 
“silencing” the target protein expression [9-10]. There are two main differences between 
shRNA and siRNA: 1) shRNA has almost same sequences as dsRNA/siRNA, except the 
two strands are connected by a loop at the end. Once the cells express shRNA, an 
enzyme, Dicer, cleaves the loops of the shRNA and turns it into functional 
dsRNA/siRNA; 2) unlike siRNA, which must be delivered from outside the cells, shRNA 
system involves endogenous expression within the cells (Figure 4.1). 
 
To avoid the detrimental effect of permanent knockdown of proteins that are vital to 
cellular function (in this case clathrin and caveolin proteins), an inducible tetracycline-
controlled transcriptional activation system was chosen to express shRNA. This inducible 
expression is a reversible gene transcription switch that turns on in the presence of the 
antibiotic Tet. Once the system is activated, the Tet-On protein binds with tetracycline 
126 
 
response elements (TREs) within the inducible expression cassette and activates the 
expression of the target gene (Figure 4.2) [11-13]. Using a commercial Tet-On shRNA 
system, we created modified HeLa and MDA-MB-231 cells to induce the production of 
shRNA that targets CLTC, CAV, and LAM expression in the presence of Tet and has 
allowed us to investigate the effect of uptake pathway knockdown on PEI-mediated gene 
delivery in vitro (Chapter 4) and in vivo (Chapter 5). 
 
4.2  Results 
 
4.2.1 shRNA Design and Cloning 
Four different DNA sequences targeting each of the three proteins were selected for this 
study using RNAi Designer program from Life Technologies. The target DNA sequences 
were chosen based on the program ranking and the region of the gene of interest in 
respect to the DNA sequence of the target protein (Table 4.1).  Complementary ss-
oligonucleotides based on the targeted DNA sequence were purchased from Integrated 
DNA Technologies (Coralville, IA) (Table 4.2). The ss-oligonucleotides were annealed 
to their respective complimentary strands to form ds-oligonucleotides. All 12 ds-
oligonucleotides were subsequently ligated into pENTR/H1/TO plasmid vector that gives 
the transfected cells the ability to express the designed shRNA sequence, provided in the 
BLOCK-iT Inducible H1 RNAi Entry Vector kit (Figure 4.3). 
 
To ensure the plasmid vector was properly annealed, restriction enzyme analysis was 
performed on all 12 annealed plasmids using MluI which should digest the plasmid at 
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two locations and result in two bands (~3000 bp and ~1000 bp) in DNA electrophoresis 
(Figure 4.4). As the gel picture shows, all 12 digested plasmids show two bands of the 
expected length, confirming that the ligation of the ds-oligonucleotides to pENTR/H1/TO 
plasmids were successful. In addition to restriction enzyme analysis, we also sequenced 
the plasmids to ensure that the inserted target DNA sequence was correct and intact after 
annealing and ligation (Table 4.3). Based on the DNA sequencing results, we were able 
to confirm that the targeting DNA sequence of all four pENTR/H1/TO-CLTC plasmids 
were present, while only two out of four pENTR/H1/TO-CAV plasmids and three out of 
four pENTR/H1/TO-LAM plasmids show intact target DNA sequences. For the 
sequences that we were unable to confirm 1) the sequencing reaction was not able to 
identify most the nucleotides or 2) the sequenced DNA sequences were incorrect. With at 
least two pENTR/H1/TO plasmids targeting CLTC, CAV, and LAM confirmed, all the 
plasmids that passed both restriction enzyme analysis and DNA sequencing were then 
subsequently transformed in competent E. coli, cloned, and purified.  
 
4.2.2 Tet-On shRNA Protein Inhibition 
HeLa and MDA-MB-231 were first transfected with pcDNA 6/TR plasmid using a 
commercial transfection reagent. A selective antibiotic, blasticidin, was added into the 
culture media to kill cells without blasticidin resistance, an indication that pcDNA 6/TR 
was not incorporated by the cells.  The modified HeLa and MDA-MB-231 colonies that 
survived the blasticidin selection were isolated and subsequently transfected, separately, 
with the pENTR/H1/TO plasmids encoding for shRNAs that target CLTC, CAV, and 
LAM DNA sequences, using the same commercial transfection reagent. Similar to 
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blasticidin selection, another antibiotic, zeocin, was used to kill modified HeLa and 
MDA-MB-231 cells that did not incorporate pENTR/H1/TO plasmid. The modified 
HeLa and MDA-MB-231 colonies that survived both antibiotic selections were isolated, 
propagated, and cultured in media containing both antibiotics to ensure the cells retained 
their dual antibiotic resistances from the incorporation of both plasmids.  
 
All the selected modified HeLa and MDA-MB-231 clones (labeled HeLa-CLTC, HeLa-
CAV, HeLa-LAM, 231-CLTC, 231-CAV, and 231-LAM for HeLa and MDA-MB-231 
cells with shRNA targeting expression of CLTC, CAV, and LAM, respectively) were 
screened with Western Blot to determine the degree of protein expression knockdown by 
varying the concentration of Tet and the incubation time. After numerous initial 
screenings, it was determined that five days incubation in the presence of 60 µg/mL Tet 
is required to induce a consistent CLTC or CAV knockdown in the modified MDA-MB-
231 cells (Figure 4.5). Using this culturing condition, the results of modified clones that 
display the best target protein knockdown are shown in Figure 4.6 and Table 4.4.  In the 
presence of Tet, HeLa-CLTC and 231-CLTC show 89% and 86%, respectively, less 
CLTC protein expression compared to the absence of Tet. HeLa-CAV and 231-CAV 
show about 52% and 58% less CAV protein expression in the presence of Tet. For 
negative control, both HeLa-LAM and 231-LAM show no difference in CLTC and CAV 
protein expression in the presence or absence of Tet. 
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4.2.3 In Vitro PEI, PEI-Tf, and PEI-Fol Transfection with Tet-Inducible shRNA 
Inhibition of Clathrin and Caveolin Protein Expression 
Various gene delivery studies were performed using the six modified cell lines showing 
the highest target protein knockdown percentage (three for HeLa and three for MDA-
MB-231) to investigate the effect of Tet-induced shRNA inhibition of CLTC and CAV 
protein on PEI gene delivery in the presence and absence of 60 µg/mL of Tet  (Figure 
4.7.A-4.7.B).  In both modified cell lines, when compared to 0 µg/mL Tet control, gene 
delivery activity increased about one to fourteen fold when CLTC was suppressed. 
Unlike CLTC, when CAV was knocked down, the gene delivery activity was reduced by 
at least half compared to in the absence of Tet at 2:1 w/w ratio or greater in both modified 
cell lines. To isolate the effect of CLTC and CAV knockdown on PEI transfection, the 
transfection data collected in the presence of Tet was normalized by its counterpart in the 
absence of Tet and also by LAM knockdown control (Equation 1 and Figure 4.8.A-
4.8.B):  
 
(231 − CLTC	@	Tet	60)/(231 − CLTC	@	Tet	0)
(231 − LAM	@	Tet	60)/(231 − LAM	@	Tet	0)
 
.. Eqn (1) 
In both modified HeLa and MDA-MB-231 cells, after normalization, PEI-mediated 
transfection improved at least two-fold when CLTC was suppressed by Tet-Inducible 
shRNA mechanism relative to CAV knockdown data.  
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Analogous gene delivery studies were performed using the same six modified cell lines, 
but using receptor-targeting PEIs, namely Tf-PEI and Fol-PEI, to study the effect of 
CLTC and CAV inhibition on receptor-targeting polyplexes (Figure 4.9.A-4.9.B). Both 
modified HeLa and MDA-MB-231 cells show significantly higher gene delivery activity 
for all five types of polyplexes when CLTC was inhibited compared to CAV inhibited 
conditions. Specifically, for modified HeLa cells, the gene delivery activity shows 
approximately five- to thirty-fold increase; for modified MDA-MB-231 cells, the gene 
delivery activity was improved by three- to ten-fold. 
 
4.3 Discussion 
To investigate the effect of clathrin- and caveolin-dependent enodcytoses on PEI gene 
delivery in vivo, we created custom cancer cell lines that inhibit CLTC and CAV protein 
expression with Tet-inducible system and also avoid the toxicity and negative effects of 
small molecule drugs and permanent knockdown of important proteins. As described in 
the previous section, a tet-inducible shRNA mechanism was successfully introduced to 
HeLa and MDA-MB-231 cells and different CLTC/CAV/LAM DNA target DNA 
sequences. Modified HeLa and MDA-MB-231clones were isolated using dual antibiotic 
selections, and the clones expressing shRNA that inhibit the protein expression of CLTC 
and CAV in the presence of Tet were found (Figure 4.6 and Table 4.4). Both HeLa-
CLTC and 231-CLTC showed over 80% CLTC protein knockdown while HeLa-CAV 
and 231-CAV showed approximately 55% CAV protein knockdown with 60 µg/mL Tet 
treatments. 
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Using the six isolated cell lines, PEI gene delivery was performed in the presence and 
absence of Tet at different PEI/DNA ratios (Figure 4.7.A-4.8.B). After normalization 
with HeLa-LAM data, in modified HeLa, the gene delivery activity of PEI was three- to 
hundred-fold higher when comparing CLTC and CAV inhibition data. Similarly in 
modified MDA-MB-231 cells, after normalization with 231-LAM data, PEI gene 
delivery was two- to six-fold better when CLTC was inhibited, relative to when CAV 
was inhibited. These results indicate that caveolin-dependent endocytosis is important to 
PEI-mediated gene delivery when using Tet-inducible shRNA protein knockdown 
mechanism to inhibit clathrin- and caveolin-dependent endocytoses, which is in good 
agreement with what we found using small molecule drugs (Chapter 2).  
 
In addition to unmodified PEI, further gene delivery studies were performed using the 
same modified cell lines and receptor-targeting PEIs (Figure 4.9.A-4.9.B). Tf-PEIs 
showed at least two-fold increase in gene delivery activity in both modified HeLa and 
MDA-MB-231 cells when comparing CLTC and CAV inhibition data, after 
normalization with LAM inhibition data. For Fol-PEIs, a similar trend was observed for 
CLTC knockdown relative to CAV knockdown, where gene delivery was improved by 
three- to twenty-fold for both modified HeLa and modified MDA-MB-231. These data 
corroborate the trends observed using receptor-targeting PEIs with small molecule drugs 
(Chapter 2) and show that regardless of receptor-targeting capability of PEI, clathrin-
dependent endocytosis does not contribute as much to successful PEI gene delivery 
compared to caveolin-dependent endocytosis.  
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4.4 Materials and Methods 
 
4.4.1 Cells and Plasmids 
The MDA-MB-231 human breast carcinoma cell line was purchased from the American 
Type Culture Collection (Manassas, VA). The HeLa human cervical carcinoma cell line 
was a gift from Dr. Sandra McMasters (University of Illinois, Urbana, IL). Cells were 
cultured according to their ATCC protocols at 37 
o
C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM). The growth medium was supplemented with 10% fetal bovine 
serum (FBS) and 10% penicillin-streptomycin. The 5.3-kilobase expression vector pGL3 
(Promega, Madison, WI), coding for firefly luciferase gene driven by the SV40 promoter 
and enhancer, was purchased from Elim Biopharm (Hayward, CA) and used without 
further purification. 
 
4.4.2 Additional Chemicals 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless specified 
otherwise. Sulfo-KMUS, 2-iminothiolane, and BCA Protein Assays were purchased from 
Thermo Fisher Scientific (Rockford, IL).  
 
4.4.3 Cloning, Sequencing, and Gel Electrophoresis 
BLOCK-iT Inducible H1 RNAi Entry Vector Kit (Life Technologies, Grand Island, NY) 
was used to create human cancer cell lines with tetracycline (Tet)-inducible protein 
knockdown. The 21-base target sense and antisense oligonucleotides sequences targeting 
clathrin heavy chain (CLTC-HC, Accession Number: nm_004895). caveolin-1 (CAV-1, 
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Accession Number: nm_00175389), and lamin A/C (LMNA, Accession Number: 
nm_170708) proteins were determined using Life Technologies’ BLOCK-iT RNAi 
Designer. The 50-nt single-stranded upper/lower shRNA ss-oligonucleotides were 
designed according to the manufacturer’s protocol and purchased from Integrated DNA 
Technologies. The complimentary ss-oligonucleotides were diluted into 200uM in double 
distilled water, annealed into ds-oligonucleotides, and stored at -20
o
C. 
 
All the ds-oligonucleotides were then annealed to the plasmid vector (pENTR/H1/TO) 
provided in the kit according to manufacturer’s protocol. The integrity of the vectors and 
sequences of the oligonucleotide inserts were then verified by restriction enzyme 
analysis, with MluI (New England Biolabs, Ipswich, MA), using DNA gel 
electrophoresis and BigDye Terminator v3.1 Cycle Sequencing kit purchased from 
Applied Biosystems; the sequencing reaction was analyzed by University of Illinois 
CORE DNA Sequencing Facility. The verified pENTR/H1/TO plasmids annealed with 
shRNA ds-oligonucleotides were then cloned in E.coli and reproduced in large quantity 
using plasmid isolation midi-prep kit (Life Technologies) and stored in -200C. 
 
4.4.4 In Vitro shRNA Transfection and Isolation 
For stable transfection of shRNA into cancer cells, TransIT-LT1 from Mirus Bio was 
used to transfect HeLa and MDA-MB-231 cells. Prior to stable transfection, selective 
antibiotic kill curve studies were performed in both cell lines with antibiotics Blasticidin 
and Zeocin (Life Technologies) to determine the optimal antibiotic concentration for cell 
selection. Following the manufacturer’s protocol, both HeLa and MDA-MB-231 cells 
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were first transfected with the plasmid pcDNA 6/TR provided in the kit with TransIT-
LT1 to introduce the cells’ Tet-inducible cassette. Briefly, in a 6-well plate, 5x10
5
 
cells/well were seeded in growth medium with serum 24 h before transfection. On the 
day of transfection, growth medium was replaced with fresh serum-free DMEM. Before 
transfection, 250 µL polyplexes in Opti-MEM (Life Technologies) were formed with 2.5 
µg of plasmid. The polyplexes were incubated at room temperature for 15 min and added 
into each well (250 µL polyplexes/well). Forty-eight hours post-transfection, cells in each 
well were transferred to individual 100 cm cell culture dishes in DMEM with 10% fetal 
bovine serum and 8 µg/mL of selective antibiotic Blasticidin. Fresh growth medium with 
10% fetal bovine and 8 µg /mL of Blasticidin was replenished every three days for three 
weeks. Massive cell death occurred during the three week period due to the presence of 
Blasticidin. Three weeks post-transfection, cells that have been stably transfected with 
pcDNA 6/TR formed colonies in culture dish. At this stage, about 30 colonies were 
isolated from each cell line and further propagated in 24-well plates in DMEM with 10% 
fetal bovine serum and 8 µg/mL of selective antibiotic Blasticidin. 
 
The isolated cells (both HeLa and MDA-MB-213) stably expressing pcDNA 6/TR were 
used for a second round of stable transfection with pENTR/H1/TO plasmid annealed with 
shRNA ds-oligonucleotides, similar to the previous stable transfection. HeLa and MDA-
MB-231 cells stably expressing pcDNA 6/TR were seeded in 6-well plates at 5x10
5
 
cells/well in growth medium with serum 24 h before transfection. Instead of pcDNA 
6/TR plasmid, TransIT-LT1 was complexed with pENTR/H1/TO plasmid with an 
shRNA insert targeting clathrin, caveolin, or lamin A/C protein expression. Forty-eight 
135 
 
hours post-transfection, all transfected cells were transferred to individual 100cm cell 
culture dishes in DMEM with 10% fetal bovine serum and 800 µg/mL of selective 
antibiotic Zeocin. Fresh growth medium with 10% fetal bovine and 800 µg/mL Zeocin 
was replenished every three days for three weeks. Massive cell death occurred during the 
three weeks period due to the presence of Zeocin. Three weeks post-transfection, cells 
that have been stably transfected with pENTR/H1/TO (targeting clathrin, caveolin, or 
lamin A/C) formed colonies in the culture dish. At this stage, about 30 colonies were 
isolated from each cell line for each plasmid targeting different protein sequences (HeLa-
CLTC, HeLa-CAV, HeLa-LAM, 231-CLTC, 231-CAV, and 231-LAM) and further 
propagated in 24-well plate in DMEM with 10% fetal bovine serum and 800 µg/mL of 
selective antibiotic Zeocin and 8 µg/mL of selective antibiotic Blasticidin. 
 
4.4.5 Western Blot 
Western Blot was used to quantify the total target protein knockdown in all the isolated 
HeLa-CLTC, HeLa-CAV, HeLa-LAM, 231-CLTC, 231-CAV, and 231-LAM cells. 
Novex 4-20% Tris-Glycine gels (Life Technologies) was used for SDS-PAGE and 
WesternBreeze Chromogenic Kit (Life Technologies) was used for Western Blot. 
Modified cells were seeded in 6-well plates for different amounts of time and at various 
concentrations of tetracycline (Tet) to determine the optimal incubation period and Tet 
concentration to obtain the highest protein knockdown %. Briefly, each modified cell line 
was seeded in a 6-well plate at 6.5x10
5
 cells/well in growth medium with Tet-System-
Approved serum (Clontech, Mountain View, CA), with 0-100 µg/mL of Tet, for 3-6 days 
and with growth medium replaced every day. After the desired incubation was reached, 
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cells were lysed, and BCA Protein Assay was used to determine total protein 
concentration in each lysate. SDS-PAGE and Western Blot were performed according to 
the Novex gel system and WesternBreeze Chromogenic Kit manufacturers’ protocols. 
Mouse monoclonal CLTC-HC antibody and rabbit monoclonal CAV-1 antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA) were used for immuno-staining. 
 
4.4.6 In Vitro Transfection with Tet-On shRNA Inducible Protein Knockdown 
All six modified cell lines were seeded in 24-well plate at 4.9x105 cells/well in growth 
medium with Tet-System-Approved serum, with and without 60 µg/mL Tet, 5 days prior 
to transfection, and old medium was refreshed on a daily basis. On the day of transfection, 
growth medium with Tet-System-Approved serum was replaced with fresh growth 
medium without serum, both with and without 60 µg/mL Tet. Prior to transfection, 50 µL 
polyplexes in 120 nM NaCl, 16 mM PIPES at pH 7.2 were formed with 0.5 µg pGL3 and 
various amounts of polymer to achieve the desired weight-to-weight ratio. The 
polyplexes were incubated at room temperature for 15 min and added into each well (50 
µL polyplexes/well). Four hours post-transfection, growth medium was replaced with 
fresh growth medium with Tet-System-Approved serum, with and without 60 µg/mL Tet, 
and incubated overnight. Twenty-four hours post-transfection, luciferase expression and 
total protein concentration were measured. 
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4.6 Tables and Figures 
 
 
Figure 4.1: Schematic of siRNA and shRNA delivery mechanisms. A) siRNA was 
delivered into the cells and bind with RNA-induced silencing complex (RISC). RISC 
separated dsRNA into ssRNA and bind the ssRNA with its complementary target mRNA, 
resulting target mRNA degradation. B) Plasmid coding for shRNA sequence was 
delivered into the cell, expressed endogenously, and produced shRNA. Subsequently, the 
hairpin portion of the shRNA was cleaved by DICER and resulted in dsRNA that is 
similar to siRNA. 
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Figure 4.2: Schematic of tetracycline activation of desired shRNA expression in cells 
transfected with Life Technologies’s BLOCK-iT Inducible H1 RNAi Entry Vector Kit. 1) 
Transfect pcDNA 6/TR plasmid into mammalian cells. 2) Use Blasticidin to select stable 
clones that express Tet repressor (TetR). 3) Transfect TetR-expressing clones with 
pENTR/H1/TO containing shRNA sequence of interest. 4) Use Zeocin to select stable 
clones that incorporated shRNA construct. In selected clones, TetR homodimers bind to 
Tet operator 2 (TetO2) to suppress the expression of shRNA. 5) Add tetracycline (Tet) to 
bind to TetR homodimers. 6) Tet and TetR homodimers binding causes conformational 
change and release from TetO2, resulting in the expression of the shRNA [13]. 
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Table 4.1: Target DNA sequences used to create tetracycline-inducible shRNA gene 
silencing cell lines targeting knockdown of CLTC, CAV, and LAM 
Target Protein Starting Nucleotide (nt) Location Target DNA Sequence 
CLTC 934 GGT TAC TTC TGA CTG GTA TAT 
CLTC 2141 GCT TGA TGC TCT GAA GAA TAA 
CLTC 2495 GGT GGC TTC TAA ATA TCA TGA 
CLTC 4497 GCA GAA CAA GCT CAT CTT TGG 
CAV 526 GCA TTT GGA AGG CCA GCT TCA 
CAV 661 GGG CAG TTG TAC CAT GCA TTA 
CAV 663 GCA GTT GTA CCA TGC ATT AAG 
CAV 781 GCA ATG TCC GCA TCA ACT TGC 
LAM 515 GCA AGA CCC TTG ACT CAG TAG 
LAM 582 GGA GTT TAA GGA GCT GAA AGC 
LAM 855 GGA ACT GGA CTT CCA GAA GAA 
LAM 1608 GCT GCG CAA CAA GTC CAA TGA 
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Table 4.2: Top strand ss-oligonucleotide sequences designed to create tetracycline-
inducible shRNA gene silencing cell lines targeting knockdown of CLTC, CAV, and 
LAM 
Target 
Protein 
Starting Nucleotide 
(nt) Location 
Top Strand ss-Oligonucleotides Design Based On Target DNA 
And Plasmid Vector Insert 
CLTC 934 CAC CGG TTA CTT CTG ACT GGT ATA TCG AAA TAT 
ACC AGT CAG AAG TAA CC 
CLTC 2141 CAC CGC TTG ATG CTC TGA AGA ATA ACG AAT TAT 
TCT TCA GAG CAT CAA GC 
CLTC 2495 CAC CGG TGG CTT CTA AAT ATC ATG ACG AAT CAT 
GAT ATT TAG AAG CCA CC 
CLTC 4497 CAC CGC AGA ACA AGC TCA TCT TTG GCG AAC CAA 
AGA TGA GCT TGT TCT GC 
CAV 526 CAC CGC ATT TGG AAG GCC AGC TTC ACG AAT GAA 
GCT GGC CTT CCA AAT GC 
CAV 661 CAC CGG GCA GTT GTA CCA TGC ATT ACG AAT AAT 
GCA TGG TAC AAC TGC CC 
CAV 663 CAC CGC AGT TGT ACC ATG CAT TAA GCG AAC TTA 
ATG CAT GGT ACA ACT GC 
CAV 781 CAC CGC AAT GTC CGC ATC AAC TTG CCG AAG CAA 
GTT GAT GCG GAC ATT GC 
LAM 515 CAC CGC AAG ACC CTT GAC TCA GTA GCG AAC TAC 
TGA GTC AAG GGT CTT GC 
LAM 582 CAC CGG AGT TTA AGG AGC TGA AAG CCG AAG CTT 
TCA GCT CCT TAA ACT CC 
LAM 855 CAC CGG AAC TGG ACT TCC AGA AGA ACG AAT TCT 
TCT GGA AGT CCA GTT CC 
LAM 1608 CAC CGC TGC GCA ACA AGT CCA ATG ACG AAT CAT 
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TGG ACT TGT TGC GCA GC 
 
 
Figure 4.3: pENTR/H1/TO plasmid vector map and annealing site of ds-oligonucleotides 
from Life Technologies’s BLOCL-iT Inducible H1 RNAi Entry Vector Kit [13] 
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Figure 4.4: Left) DNA electrophoresis of pENTR/H1/TO plasmids annealed with ds-
oligonucleotides targeting CLCT, CAV, and LAM after MluI restriction enzyme 
digestion. Lane 1&15: ladder, lane 2-5: pENTR-CLTC, lane 6-9: pENTR-CAV, lane 10-
13: pENTR-LAM, and lane 14: undigested plasmid as negative control. Right) DNA 
ladder bp map 
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Table 4.3: DNA sequencing results to confirm the incorporation of target DNA sequence 
into pENTR/H1/TO plasmids 
Target Protein Starting Nucleotide (nt) Location Target DNA Sequence Confirmed 
CLTC 934 Yes 
CLTC 2141 Yes 
CLTC 2495 Yes 
CLTC 4497 Yes 
CAV 526 No 
CAV 661 No 
CAV 663 Yes 
CAV 781 Yes 
LAM 515 Yes 
LAM 582 No 
LAM 855 Yes 
LAM 1608 Yes 
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Figure 4.5: Tetracycline inducible shRNA CLTC and CAV knockdown in modified 
MDA-MB-231 cells by Western blot. % protein knockdown is calculated based on 
densiometry after 5 days in the presence of tetracycline 
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Figure 4.6: Western Blot images showing protein knockdown of the corresponding 
modified Tet-Inducible shRNA cell line. Cells are lysed after six days’ incubation in the 
presence of 0 or 60 µg/mL Tet  
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Table 4.4: Tet-Inducible shRNA cell lines’ target protein knockdown % based on 
Western blot 
Tet-Inducible 
shRNA Cell Line 
Starting Nucleotide (nt) 
Location 
Approximate Target 
Protein Knockdown % 
231-CLTC 2141 86 
231-CAV 663 52 
HeLa-CLTC 4497 89 
HeLa-CAV 663 58 
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Figure 4.7.A: In vitro unmodified PEI transfection of Tet-Inducible shRNA HeLa after 
six days of incubation in the presence of 60 µg/mL Tet. Each set of data is normalized to 
Tet-absent control (N=4, error bars represent standard deviation; t-test: *,**,^, †,‡, 
p<0.05 comparing gene delivery activity for the same polyplexes in the presence and 
absence of Tet) 
 
  
149 
 
 
Figure 4.7.B: In vitro unmodified PEI transfection of Tet-Inducible shRNA MDA-MB-
231 after six days of incubation in the presence of 60 µg/mL Tet. Each set of data is 
normalized to Tet-absent control (N=4, error bars represent standard deviation; t-test: 
*,**,^, †,‡, p<0.05 comparing gene delivery activity for the same polyplex in the 
presence and absence of Tet) 
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Figure 4.8.A: In vitro unmodified PEI transfection of Tet-Inducible shRNA HeLa after 
six days of incubation in the presence of 60 µg/mL Tet. Data is normalized according to 
Equation 1 (N=4, error bars represent standard deviation; t-test: *,**, †,‡, p<0.05 
comparing gene delivery activity for the same polyplex in the presence and absence of 
Tet) 
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Figure 4.8.B: In vitro unmodified PEI transfection of Tet-Inducible shRNA MDA-MB-
231 after six days of incubation in the presence of 60 µg/mL Tet. Data is normalized 
according to Equation 1 (N=4, error bars represent standard deviation; t-test: *,**, †,‡, 
p<0.05 comparing gene delivery activity for the same polyplex in the presence and 
absence of Tet) 
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Figure 4.9.A: In vitro unmodified PEI, Tf- PEI, and Fol-PEI transfections of Tet-
Inducible shRNA HeLa after six days of incubation in the presence of 60 µg/mL Tet. 
Data is normalized according to Equation 1 (N=4, error bars represent standard deviation; 
t-test: *,**, †,‡, p<0.05 comparing gene delivery activity for the same polyplex in the 
presence and absence of Tet) 
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Figure 4.9.B: In vitro unmodified PEI, Tf- PEI, and Fol-PEI transfections of Tet-
Inducible shRNA MDA-MB-231 after six days of incubation in the presence of 60 
µg/mL Tet. Data is normalized according to Equation 1 (N=4, error bars represent 
standard deviation; t-test: *,**, †,‡, p<0.05 comparing gene delivery activity for the same 
polyplex in the presence and absence of Tet)
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Chapter 5 
The Effect of Clathrin- and Caveolin-Dependent Endocytosis on PEI-
Mediated Gene Delivery in HeLa and MDA-MB-231 Xenograft Murine 
Tumor Model 
 
5.1 Introduction 
Inducible shRNA expression provides researchers a flexible tool to study the effects of 
specific proteins on tumorigenesis. For example, Kappel et al. used a doxycycline 
inducible shRNA system to downregulate polo-like kinase 1 (Plk1) in the presence of 
doxycycline, showing that doxycycline knockdown of Plk1 arrested HeLa cell growth 
and caused significant inhibition in tumor growth [1]. Czauderna et al. inhibited 
phosphatidylinositol 3-kinase expression in human prostate cancer cells and showed that 
shRNA expression was stable 56 days post-doxycycline induction in vivo [2]. Using both 
an inducible shRNA system and transient siRNA transfection, Gillespie et al. were able 
to knockdown the expression of hypoxia-inducible factor-1α (HIF-1α), which plays an 
important role in tumor growth, and successfully reduced HIF-1α expression and 
decreased tumor size by over 60% in both glioma cells in vitro and glioma mouse tumor 
model [3].  
 
In Chapter 4, we created modified HeLa and MDA-MB-231 cells with a Tet inducible 
shRNA system that targets CLTC and CAV proteins in the presence of Tet. When CLTC 
and CAV were inhibited by shRNA, the in vitro gene delivery results were in agreement 
with small molecule drugs inhibition data. However, due to fundamental differences 
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between cell culture and in vivo tumors, it is critical to verify in vitro results in an animal 
model in order for the experimental data to be useful in future clinical studies.  
 
In the current chapter, we used the customized HeLa and MDA-MB-231 cells described 
in Chapter 4 to inhibit the expression of clathrin (CLTC), caveolin (CAV), and lamin 
A/C (LAM) in the presence of Tet and investigate the effect of endocytic uptake pathway 
on PEI gene delivery in xenograft tumor model. Specifically, we injected the modified 
cancer cells into immune-suppressed nude mice and allowed tumors to develop. When 
tumors reached the desired size, Tet-containing sterile water was fed to the specific mice 
groups to induce shRNA expression, while the non-induced group was fed with sterile 
water only, and polyplexes were administered via intratumoral injection. One would 
expect successful in vivo gene delivery should show similar dependence on caveolin-
dependent endocytosis as its in vitro counterpart. 
 
5.2  Results 
 
5.2.1 Establishment of Xenograft Tumors and Confirmation of Tet-Induced 
Knockdown of CLTC and CAV In Vivo 
Six modified cell lines (HeLa-CLTC, HeLa-CAV, HeLa-LAM, 231-CLTC, 231-CAV, 
and 231-LAM) were subcutaneously injected into the flanks of mice. Approximately 4 
weeks post injection, tumors that were 8-10 mm in outer diameter had developed. For the 
Tet induction group, sterile water with added Tet was fed to the mice, and vice versa. 
Four days after feeding the mice with Tet water, PEI/pGL3 polyplexes were injected 
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intratumorally for gene delivery experiments; for immunoblotting experiments, tumors 
were not transfected. On Day 7, mice were euthanized and tumors were extracted (Figure 
5.1).  
 
Western Blot was used to quantify the downregulation of the target proteins, CLTC and 
CAV, from shRNA-incorporated tumor lysate extracted from the group of mice fed with 
water only as well as the group fed with Tet water to compare their respective target 
protein knockdown (Figure 5.2 and Table 5.1). When mice were fed with Tet water, 
231-CLTC showed 58% knockdown of CLTC, while 231-CAV and 231-LAM showed 
only 3% and -4% (negative knockdown indicates more target protein was in the tumor 
tissue extracted from mice fed with Tet water). Similar to its 231-CLTC counterpart, 90% 
of CLTC protein was downregulated for HeLa-CLTC; HeLa-CAV and HeLa-LAM 
showed no CLTC protein knockdown, as expected. 231-CAV and HeLa-CAV showed 
63% and 35% target CAV protein knockdown, respectively, and the other modified cells 
that did not target CAV expression resulted in no CAV knockdown. These 
immunoblotting results indicate that the inducible shRNA system was activated in tumor 
tissue, resulting in inhibition of target protein expression when mice were fed with Tet 
added water vs. plain water only. 
 
5.2.2 In Vivo PEI Transfection in murine xenograft tumor model 
With the target protein knockdown of the xenograft tumors in the presence of Tet 
confirmed, PEI tumor gene delivery study was performed by injecting polyplexes 
intratumorally (Figure 5.3.A-5.3.B). For HeLa-CLTC tumors, comparing the gene 
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delivery activity between the tumor lysates in the absence and presence of Tet, PEI 
transfection efficacy increased by about six-fold. HeLa-CAV tumors showed 50% 
decreased gene delivery activity when the mice were fed with Tet water. Although HeLa-
LAM tumors showed similar reduction in transfection as HeLa-CAV tumors, there was 
no statistically significant difference in gene delivery activity between water-only groups 
and Tet water groups. For MDA-MB-231 tumors, 231-CLTC showed approximately two-
fold increase in gene delivery activity comparing between the 0 and 5 mg/mL Tet groups. 
In the presence of Tet, the gene delivery activity of 231-CAV decreased by about 20%; 
however, the difference was not statistically significant. 231-LAM showed no difference 
in gene delivery activity in the presence of Tet.  
 
Similar to the in vitro experiment (Chapter 4), the transfection data collected in the 
presence of Tet was normalized by its counterpart in the absence of Tet and also by LAM 
knockdown control to isolate the specific effects of CLTC and CAV knockdown on PEI 
transfection (Figure 5.4). For modified HeLa tumors, after normalization, PEI gene 
delivery was 14-fold more efficient when CLTC was inhibited compared to when CAV 
was inhibited.  For modified MDA-MB-231 tumors, there was a 2.5-fold increase in gene 
delivery activity when comparing CLTC and CAV inhibition. However, the improvement 
in transfection was not statistically significant. 
 
5.3 Discussion 
In this chapter, we investigated the effects of inhibiting CLTC- and CAV-dependent 
endocytoses on in vivo PEI-mediated gene delivery by using inducible shRNA HeLa and 
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MDA-MB-231 cells (described in Chapter 4), allowing us to ultimately determine which 
of the two pathways is more important to successful in vivo PEI-mediated gene delivery. 
A murine xenograft tumor model was created by injecting inducible shRNA cell lines 
into NIH-III nude mice subcutaneously. Using Western Blot, we were able to quantify 
the percentage knockdown of target proteins, CLTC and CAV, between the groups of 
mice that were fed with water only and with Tet–containing water (Figure 5.2 and Table 
5.1). For modified MDA-MB-231 tumors, 231-CLTC and 231-CAV show 58% and 63% 
of their respective target protein inhibition in the presence of Tet, compared to their 
induction-free counterparts. For the controls, 231-CLTC, 231-CAV, and 231-LAM show 
minimal to no knockdown for their untargeted proteins CAV, CLTC, and both, 
respectively. Similar to modified MDA-MB-231 tumors, modified HeLa tumors show 
approximately 90% and 35% respective target protein knockdowns for HeLa-CLTC and 
HeLa-CAV. Compared to the in vitro knockdown data (Chapter 4: Figure 4.6 and 
Table 4.4), in vivo protein inhibition show similar trends but lower overall target protein 
knockdown. This is likely due to the fact that monolayer cell culture was in direct contact 
with Tet in culture media, while tumors absorbed Tet through circulation in mice, 
resulting in reduced Tet induction efficacy. Comparing the relative knockdown of CLTC 
and CAV proteins in vitro, inducible shRNA system was more effective in 
downregulating CLTC than CAV. Similarly, in vivo knockdown of CLTC was higher 
than CAV for modified HeLa and equally efficient in modified MDA-MB-231. These 
data indicate that CAV protein was more difficult to inhibit than CLTC protein for HeLa 
and MDA-MB-231 using inducible shRNA system. Overall, the protein knockdown 
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results confirmed that the custom inducible shRNA cells were capable of target protein 
inhibition in both in vitro culture and xenograft tumor model.  
 
By using murine inducible shRNA xenograft tumor model, we studied the effect of 
CLTC- and CAV-dependent endocytoses on PEI-mediated gene delivery (Figure 5.3.A-
5.3.B).  When CLTC protein expression was inhibited for HeLa-CLTC in the presence of 
Tet, the gene delivery activity increased by about six-fold. However, when CAV protein 
was downregulated for HeLa-CAV, the gene delivery activity was decreased by 50%. For 
the control, the difference between the gene delivery activity for HeLa-LAM in the 
presence and absence of Tet was statistically not significant, which means the effect of 
LAM inhibition was minimal for PEI gene delivery. After normalizing the transfection 
data with no Tet induction and HeLa-LAM (Figure 5.4), the result indicates that gene 
delivery activity for modified HeLa xenograft tumor improved by over 15-fold when 
comparing CLTC inhibition with CAV inhibition. Overall, these data show that the HeLa 
xenograft tumor model utilized CAV-dependent endocytosis for efficient PEI-mediated 
gene delivery.  
 
For MDA-MB-231 modified tumors, gene delivery activity was improved by about two-
fold when CLTC was inhibited for 231-CLTC in the presence of Tet. Although 231-CAV 
shows a reduction of transfection by about 20% when CAV was downregulated, this 
difference was unfortunately statistically insignificant. When LAM was inhibited, 231-
LAM shows similar gene delivery activity in the absence and presence of Tet, which is 
what we expected from our control groups. Based on these data, we can conclude that, for 
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modified MDA-MB-231 xenograft tumors, CLTC-dependent endocytosis is not critical to 
successful in vivo PEI-mediated gene delivery. When the gene delivery data were 
normalized with no Tet control and 231-LAM groups, the results demonstrate that in vivo 
PEI gene delivery activity shows an approximately 2.5-fold increase when CLTC was 
inhibited, compared to when CAV was inhibited. However, the errors of 231-CAV and 
231-LAM data, with and without Tet, were large and propagated further after two 
normalizations, resulting in a statistically insignificant difference between the normalized 
231-CLTC and normalized 231-CAV data. Comparing the modified MDA-MB-231 in 
vivo transfection result with its in vitro counterpart, both experiments show similar order 
of magnitude improvement in gene delivery activity when CLTC was inhibited versus 
when CAV was inhibited (Chapter 4: Figure 4.8.B and Figure 5.4). Thus, the 
statistically insignificant difference between 231-CLTC and 231-CAV in in vivo 
transfection was likely an artifact of variability inherent to animal testing. 
 
5.4 Materials and Methods 
 
5.4.1 Cells and Plasmids 
The modified HeLa human cervical carcinoma cell and MDA-MB-231 human breast 
carcinoma cell line were created according to Material and Methods in Chapter 4. 
Cells were cultured according to their ATCC protocols at 37 
o
C and 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM). The growth medium was supplemented 
with 10% fetal bovine serum (FBS) and 10% penicillin-streptomycin. The 5.3-kilobase 
expression vector pGL3 (Promega, Madison, WI), coding for firefly luciferase gene 
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driven by the SV40 promoter and enhancer, was purchased from Elim Biopharm 
(Hayward, CA) and used without further purification. 
 
5.4.2 Additional Chemicals 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless specified 
otherwise. BCA Protein Assays were purchased from Thermo Fisher Scientific (Rockford, 
IL).  
 
5.4.3 Choice of Nude Mice and Xenograft Tumor Implantation  
In this study, Charles River NIH-III 201 homozygous nude mouse (Wilmington, MA) 
was used to develop human xenograft tumor model. NIH-III nude mice, in addition to the 
absence of thymus and T-cell function, have x-linked immune defect (xid) and beige (bg) 
mutation that deregulate the immune system function [4]. To implant xenograft tumor, 
the right flanks of four weeks old NIH-III nude mice were inoculated subcutaneously 
with 1x10
7
 cells of modified cancer cell lines in 100 µL of PBS. Each modified cell line 
was injected into two groups of six mice.  
 
5.4.4 In Vivo Transfection 
When xenograft tumors reach ~8-10 mm in OD, the groups of mice intended for Tet-
induction were  fed sterile tap water with 5 mg/mL of Tet and 5 mM saccharin (to mask 
the bitter taste of Tet in water) for 7 days, while the groups intended for no Tet-induction 
would be fed sterile tap water with 5 mM saccharin. Fresh water with (or without) Tet 
was prepared every 2 days [5]. On Day 4, prior to transfection, 50 µL polyplexes in a 
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solution of 120 mM NaCl and 16 mM PIPES at pH 7.2 were formed with 75 µg pGL3 at 
4:1 polymer-DNA weight-to-weight ratio. The polyplexes were incubated at room 
temperature for 15 min and injected intratumorally. On Day 7, mice were euthanized with 
isoflurane, followed by cervical dislocation. 
 
5.4.5 Tumor Extraction, Luciferase Assay, and Western Blot 
Transfected tumor extraction and processing for luciferase measurement was modified 
from Manthorpe et al. [6]. Tumors were extracted immediately from euthanized mice and 
transferred to 500 µL of cell culture lysis reagent (Promega) in 1.5 mL microcentrifuge 
tubes and homogenized. Homogenized tumors were then vortexed for 15 minutes, 
followed by three freeze-thaw cycles in liquid nitrogen and 37 °C water bath. Samples 
were spun at max speed in a microcentrifuge for 10 minutes, and the supernatants were 
collected. The luciferase expression and total protein concentration were then measured 
as previously described. For Western Blot, similar protocol was used to treat extracted 
tumor. SDS-PAGE and Western Blot were performed according to Novex gel system and 
WesternBreeze Chromogenic Kit manufacturers’ protocols (Life Technologies). Mouse 
monoclonal CLTC-HC antibody and rabbit monoclonal CAV-1 antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) were used for immuno-staining. 
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5.6 Tables and Figures 
 
 
Figure 5.1: Schematic of murine xenograft tumor implantation and in vivo transfection. 
NIH-III nude mice were injected with 10
7
 modified cancer cells. Tumors reached ~8-10 
mm in OD approximately 4 weeks post injection. For Tet induction group, mice were fed 
with Tet added water. For non-induction group, mice were fed with water. Four days 
after feeding with Tet water, PEI/pGL3 polyplexes were injected intratumorally for 
transfection experiment. For immunoblotting analysis, tumors were left untouched.  On 
Day 7, mice were euthanized and tumors were extracted for either luciferase analysis or 
Western blot. 
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Figure 5.2: Western Blot images showing protein knockdown of the corresponding 
modified Tet-Inducible shRNA tumor tissue. Tumors were extracted after mice were fed 
with either water or Tet added water (5 mg/mL) for seven days. 
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Table 5.1: Tet-Inducible shRNA tumor tissue target protein knockdown % based on 
Western blot. Negative value indicates more target protein was present in tumor tissue 
when mice were fed with 5 mg/mL Tet water. 
Approximate Target Protein Knockdown, % 
Tet-Inducible 
shRNA Tumor Tissue 231-CLTC 231-CAV 231-LAM 
CLTC Stain 58 3 -4 
CAV Stain -5 63 -2 
Approximate Target Protein Knockdown, % 
Tet-Inducible 
shRNA Tumor Tissue HeLa-CLTC HeLa-CAV HeLa-LAM 
CLTC Stain 90 -1 -9 
CAV Stain -10 35 -9 
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Figure 5.3.A: In vivo unmodified PEI transfection of Tet-Inducible shRNA HeLa tumors 
after mice were fed with 0 or 5 mg/mL Tet water for seven days. (N=6, error bars 
represent standard deviation; t-test: *, † p<0.05 comparing gene delivery activity for the 
same polyplex in the presence and absence of Tet) 
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Figure 5.3.B: In vivo unmodified PEI transfection of Tet-Inducible shRNA MDA-MB-
231 tumors after mice were fed with 0 or 5 mg/mL Tet water for seven days. (N=6, error 
bars represent standard deviation; t-test: *, p<0.05 comparing gene delivery activity for 
the same polyplex in the presence and absence of Tet) 
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Figure 5.4: In vivo unmodified PEI transfection of Tet-Inducible shRNA HeLa and 
MDA-MB-231 tumors after mice were fed with 0 or 5 mg/mL Tet water for seven days. 
Data is normalized according to Equation 1 in Chapter 4 (N=6, error bars represent 
standard deviation; t-test: *, p<0.05 comparing gene delivery activity for the same 
polyplex in the presence and absence of Tet) 
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Chapter 6 
COMMENTS AND FUTURE WORK 
 
6.1 Comments and future work 
The first half of this thesis has examined effective uptake pathways for in vitro gene 
delivery of polyethylenimine (PEI) and its derivatives by using small molecule drugs to 
inhibit clathrin- and caveolin-dependent endocytoses. In Chapter 2, we have 
demonstrated that the success of unmodified PEI depends heavily on caveolin-dependent 
endocytosis in both HeLa and MDA-MB-231 cells. In addition, PEI conjugated with 
ligands targeting clathrin- and caveolin-associated receptors (Tf-PEI and Fol-PEI) 
produces similar results.  Specifically, gene delivery activity of receptor targeting 
polyplexes increased when clathrin-dependent endocytosis was inhibited and vice versa, 
regardless of intended target pathways of the Tf-PEI and Fol-PEI, which is in good 
agreement with Gabrielson et al [1]. In Chapter 3, we have further explored the effect of 
endocytic uptake pathways on PEI derivatives that have previously shown superior 
transfection capability compared to unmodified PEI, namely biodegradable PEI (D.PEI) 
and acetylated PEI (AcPEI) [2-4]. The three D.PEIs and one AcPEI studied in this 
chapter have shown similar trends to unmodified PEI, where caveolin-dependent 
endocytosis contributes more to successful gene delivery than clathrin-dependent 
endocytosis. Furthermore, the effects of clathrin- and caveolin-uptake pathway inhibition 
were more significant for higher molecular weight D.PEIs than lower molecular weight 
D.PEI and AcPEI. These results suggest that the scale of uptake pathway effects was 
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somewhat dependent on molecular weight of the polymer and the DNA dissociation of 
the polyplexes. 
 
In the second half of this thesis, we described the process used to create customized 
cancer cell lines, as well as our studies of endocytic uptake pathway effects on PEI gene 
delivery in murine xenograft tumor model. In Chapter 4, a tetracycline (Tet)-inducible 
shRNA knockdown system was incorporated into HeLa and MDA-MB-231 cells in order 
to selectively inhibit the clathrin (CLTC), caveolin (CAV), or lamin A/C (LAM) protein 
expression in the presence of Tet. Using these shRNA modified cell lines, we showed 
again that caveolin-dependent endocytosis plays an important role for successful PEI, Tf-
PEI and Fol-PEI gene delivery, similar to the results in small molecule drug studies. 
These results confirm two things: 1) the effect of knocking down a crucial protein 
associated with particular uptake pathway is similar to pathway inhibition using drugs, 
and 2) the Tet-inducible shRNA knockdown mechanism was effective in inhibiting the 
target protein.  
 
Immunodeficient nude mice (NIH-III) were used to create murine xenograft tumor 
models via injection with modified HeLa or MDA-MB-231. Immunoblotting showed that 
Tet-inducible shRNA system in both modified HeLa and MDA-MB-231 tumors inhibits 
target protein expression when mice were fed with Tet-containing water. The gene 
delivery data for modified HeLa tumors indicate that there was an improvement of 
approximately 15-fold when comparing CLTC and CAV inhibition. Similarly, modified 
MDA-MB-231 tumor transfection experiments show that there was a 2.5-fold increase in 
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gene delivery activity; however, the difference is not statistically significant. Overall, the 
in vivo xenograft tumor model gene delivery study proves that 1) Tet-inducible shRNA 
system in modified HeLa and MDA-MB-231 successfully inhibited target protein 
expression in xenograft tumor model, 2) CAV-dependent endocytosis is critical to 
successful PEI-mediated gene delivery, and 3) CLTC-dependent endocytosis does not 
contribute to PEI-mediated gene delivery.  
 
In this dissertation, we have characterized the effects of endocytic uptake pathways on in 
vitro PEI, Tf-PEI, Fol-PEI, D.PEI, and AcPEI gene delivery. Similar gene delivery 
studies were performed using PEI and shRNA modified cancer cell lines in murine 
xenograft tumor model. To optimize non-viral gene delivery, it is critical for researchers 
to understand thoroughly the endocytic effects on polymeric gene delivery vectors by 
fully characterizing uptake mechanisms used by PEI polyplexes, in both greater depth 
and in pathways beyond clathrin and caveolin. For future work, using the modified cell 
lines and polymers studied in this thesis project, we could further investigate the effect of 
CLTC- and CAV-dependent endocytoses on targeted PEIs and PEI derivatives. 
Specifically, the effects of structure, size, and zeta potential on both the gene delivery 
efficacy and biodistribution of PEI and PEI derivative polyplexes could be investigated 
after in vivo transfection when either CLTC or CAV are inhibited. Such studies would 
provide insight into which factors play an important role in non-viral gene delivery 
vehicle design when certain endocytic uptake mechanisms are inhibited in vivo. 
Furthermore, we could also study the effects of CLTC and CAV endocytoses on other 
polymeric vectors that have shown promising in vivo tumor transfection, including PEG-
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PEI, PLGA-PEG, poly(amine-co-ester), which, in turn, would help to improve overall 
non-viral gene delivery design by synergistically combining the benefits of superior 
vector design and effective uptake pathway [5-7]. Lastly, in addition to testing new gene 
delivery carriers, we could focus on fully characterizing the effects of other uptake 
mechanisms, such as CLIC/GEEC, IL2Rβ, and Arf6, on PEI-mediated gene delivery 
using Tet-inducible shRNA knockdown system in vitro as well as in xenograft tumor 
model [8-9].  
 
In conclusion, the work described here provides an effective method to study the effect of 
protein knockdown for gene delivery in vitro and in vivo.  Additional research is needed 
to incorporate different aspects of polymeric gene delivery, including vector design, cell 
targeting, endocytosis, intracellular trafficking, and nuclear entry in order to improve 
non-viral gene delivery significantly and make it comparable to viral gene delivery 
efficacy.
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